Category Archives: Patent / 专利

Two Intellectual Property Plans for the 15th Five-Year Period: What Changes for Foreign R&D Centres

  • The State Council has issued the Intellectual Property Protection and Utilisation 15th Five-Year Plan, a directional document setting goals to 2030 rather than creating new filing channels.
    国务院印发《知识产权保护和运用”十五五”规划》,这是一份设定 2030 年目标的方向性文件,并未新设申报通道。
  • By 2030 the plan targets more than 22 high-value invention patents per 10,000 people, at least six more than at the end of the previous plan period.
    规划提出到 2030 年每万人口高价值发明专利拥有量超过 22 件,较”十四五”末增长 6 件以上。
  • The China National Intellectual Property Administration issued its Patent Examination Rules plan on 3 November 2026, with four task areas and seven special projects.
    国家知识产权局于 2026 年 11 月 3 日印发《专利和商标审查”十五五”规划》,设四方面重点任务与 7 个专项工程。
  • Examination standards for big data, Artificial Intelligence Inventions and gene technology will be revised, so specifications and claims should leave room to adapt.
    大数据、人工智能发明与基因技术的审查标准将予完善,说明书与权利要求应预留调整空间。
  • The plan will study protection objects for virtual and augmented reality designs and adjust submission rules for Graphical User Interfaces in due course.
    规划将研究虚拟现实、增强现实等数字领域外观设计保护客体,并适时调整图形用户界面提交规则。
  • Work on Standard Essential Patents examination policy continues, which matters to companies involved in standard setting and FRAND compliance.
    标准必要专利审查政策将继续完善,这对参与标准制定与 FRAND 合规的企业尤为重要。
  • Trademark measures target bad-faith filings through systematic regulation and penetrative supervision of applicants, changing how foreign brands plan their remedies.
    商标措施通过系统规制与对申请主体的穿透式监管治理恶意申请,改变外资品牌规划救济路径的方式。
  • Public training on foreign patent examination policy and information sharing is part of the plan, giving foreign companies a talent and training resource.
    加强国外专利审查政策公共培训与信息共享是规划内容之一,为外资企业提供了人才与培训资源。

Two Intellectual Property Plans for the 15th Five-Year Period: What Changes for Foreign R&D Centres | 知识产权两个”十五五”规划:外资研发中心要看的三个方向

Overview

In early November 2026 two five-year plans on intellectual property were released. The State Council issued the Intellectual Property Protection and Utilisation 15th Five-Year Plan; on 3 November 2026 the China National Intellectual Property Administration issued its plan for patent and trademark examination over the same period.

Both are directional documents: no application window, quota or threshold, only the direction examination practice will follow to 2030.

Two plans, one direction

The State Council plan anchors the building of an intellectual property power with Chinese characteristics and world standards. By 2030, comprehensive strength and international competitiveness should be further enhanced across protection, market value, public services, management and international cooperation, and the building of that power should reach a decisive stage.

Its headline indicator is more than 22 high-value invention patents per 10,000 people, at least six more than at the end of the previous plan period — a resource-allocation signal as much as a target.

The examination plan is the operational half. Its goal is that by 2030 a first-class examination institution with Chinese characteristics and world standards is basically established, with a maturing system, better quality, stronger support for development and globally leading capability.

Patent examination: emerging fields first

The patent side carries five deployments. It will strengthen alignment between China’s patent legal system and high-standard trade rules such as CPTPP; promptly improve examination standards for big data, artificial intelligence and gene technology; study and improve standards for bio-breeding and green low-carbon fields; improve the examination mechanism for traditional Chinese medicine patents; and establish an “AI plus” examination management mechanism.

For an applicant, substantive standards are moving, not only procedure; a specification drafted to current practice may need revisiting.

Seven special projects

The plan sets seven special projects, among them one on patent examination rules for emerging fields, one on trademark examination quality and one on “AI plus” examination.

The emerging-fields project lists the work to watch: the definition of a person skilled in the art and the scope of prior art for AI-assisted inventions; the inventor identity and patentability of AI-generated inventions; a declaration system for AI use in applications; improved policy for standard essential patents; and protection objects for virtual and augmented reality designs, with rules for graphical user interfaces to be adjusted in due course.

Every verb there is study, improve or adjust — none is a commitment to a date.

Trademarks: bad faith and penetrative supervision

The plan meets trademark registration demand from emerging fields including artificial intelligence and virtual reality, and explores pre-examination of applications there. It deepens treatment of deceptive trademarks, including ex officio invalidation of registered marks, strengthens systematic regulation of bad-faith filings, advances penetrative supervision of applicants and improves coordinated governance of bad-faith agency.

For a foreign brand owner the object of supervision becomes the filing chain, not the filing; monitoring, opposition and invalidation remain the tools.

International cooperation

The plan covers consultation under the WIPO framework, work through the five offices of China, the United States, Europe and Japan and the BRICS mechanism, and cooperation on examination, informatisation and training with Belt and Road partners.

Three lines for a foreign R&D centre

First, emerging-field standards. Where a portfolio rests on AI, big data or gene technology, drafting should leave room for a revised definition of the skilled person and a wider prior-art scope.

Second, designs. If GUI, VR or AR protection matters, submission rules are the point to watch and a design inventory is the preparation.

Third, standards. Where the company contributes to standards, examination policy for standard essential patents and FRAND practice should be tracked together.

The plan also calls for public training on foreign patent examination policy and information sharing — a resource for foreign companies in China, not an obligation.

What the plan does not promise

No new application channel is created. No grant period is promised. No category is said to be examined faster. Where the plan says study or explore, the rule has not changed yet.

Practical steps

  • Audit the portfolio for technical contribution rather than count.
  • For AI-related filings, prepare inventor attribution and a use declaration in advance.
  • List GUI and design assets, and track the submission rules for each.
  • Monitor trademark filings and keep an opposition and invalidation calendar.
  • For standards work, align the patent and FRAND positions before contributing.
  • Use the public training and information-sharing channels on examination policy.

Outlook

The plans describe a system that examines fewer things more carefully. For a foreign R&D centre the question is not whether filings become easier, but whether the portfolio can be explained in terms of technical contribution.

Sources

  • 国家知识产权局·《专利和商标审查”十五五”规划》印发:https://www.cnipa.gov.cn/art/2026/11/3/art_53_208900.html
  • 中国政府网·《知识产权保护和运用”十五五”规划》:https://www.gov.cn/
  • 国家知识产权局:https://www.cnipa.gov.cn/
  • 国家知识产权局·知识产权保护与运用政策专栏:https://www.cnipa.gov.cn/

知识产权两个”十五五”规划:外资研发中心要看的三个方向

概述

2026 年 11 月初,两份知识产权五年规划先后发布。国务院印发《知识产权保护和运用”十五五”规划》;2026 年 11 月 3 日,国家知识产权局印发《专利和商标审查”十五五”规划》。

两份都是方向性文件。它们不设申报窗口、不设名额、不设新的门槛,设定的是到 2030 年审查实践要走的方向。这也正是它们值得在配套规则出台之前先读一遍的原因。

需要先说明一点:规划不是法规。规划里写的”研究””探索””完善”,在转化为审查指南、部门规章或公告之前,不会改变当下某一类申请的实际审查结果。把它当作”即将生效的新规”来排期,容易高估短期影响;把它当作”未来五年的资源配置说明书”来读,判断会更稳。

两份规划的关系也需要分清。国务院规划管的是”保护与运用”,回答制度要往哪儿走;审查规划管的是”审查”,回答专利与商标在窗口那一端怎么被看。前者影响企业为什么申请,后者影响申请怎么写。

两份规划,一个方向

国务院规划锚定建设中国特色、世界水平的知识产权强国。到 2030 年,知识产权综合实力和国际竞争力进一步增强,保护更加有力、市场价值更加彰显、公共服务更加优质、综合管理体制更加高效、国际合作更加深入,知识产权强国建设取得决定性进展。

其核心预期性指标是:每万人口高价值发明专利拥有量超过 22 件,较”十四五”末增长 6 件以上。这类指标既是目标,也是资源配置信号——审查资源与评价导向会向”高价值”倾斜。

审查规划是操作层面的那一半。目标是到 2030 年,具有中国特色、世界水平的一流专利商标审查机构基本建成,审查制度日趋完善,审查质量显著提升,支撑发展更加有力,国际合作持续深化,审查能力全球领先。

专利审查:新兴领域先行

专利一侧有五项具体部署。加强中国专利法律制度与 CPTPP 等国际高标准经贸规则的衔接;及时完善大数据、人工智能、基因技术等新兴领域专利审查标准;研究完善生物育种、绿色低碳等重点领域专利审查标准;完善中医药专利审查机制;建立”人工智能+”审查业务管理机制。

对申请人而言,有用的读法是:变化落在实体标准上,而不只是程序上。按当下实践撰写的说明书,在这几个领域的标准完善之后可能需要回看。撰写的预留空间,比事后补救便宜。

具体到操作,可以在三个地方预留:一是权利要求的层次,独立权利要求写得过窄,标准调整后很难通过分案或修改补回范围;二是说明书中对技术效果的记载,标准一旦强调某类效果,缺少记载的部分无法后补;三是实施例的数量与分布,覆盖不足的实施例在审查趋严时会成为短板。

七个专项工程

规划设 7 个专项工程,其中包括新兴领域专利审查规则完善工程、商标审查质量提升工程、”人工智能+”审查工程等。

新兴领域工程列出了最受关注的一组工作:研究人工智能辅助发明的本领域技术人员定义与现有技术范围;研究人工智能生成发明的发明人身份和可专利性;研究专利申请中的人工智能使用声明制度;完善标准必要专利审查政策;研究虚拟现实、增强现实等数字领域外观设计保护客体,适时调整图形用户界面提交规则。

这一串动作的动词都是”研究””完善””调整”。它们不构成对时间表或结果的承诺。

专项工程的意义在于资源投向。列进工程的事项,通常会先有课题、再有指南、最后才是规则文本;对企业的含义是:这些领域的审查实践会在未来几年内持续变化,一次性的应对不够,需要有跟踪机制。

商标:恶意申请与穿透式监管

商标一侧,规划回应新兴领域的商标注册需求,探索研究人工智能、虚拟现实等领域对商标注册的需求,探索开展新兴领域商标注册申请预核;深化对带有欺骗性的商标治理,对已注册的依职权宣告无效;加强对恶意申请商标注册行为的系统规制,推进商标申请行为主体穿透式监管;加强对商标代理机构恶意代理行为的协同治理。

对外资品牌权利人来说,方向是把”申请链条”而不只是”申请”作为监管对象。监控、异议、无效仍是实务工具,变化的是这些工具所处的执法环境。

穿透式监管的含义值得单独说一句:监管关注的不只是提交了什么,还包括谁在提交、代理机构在其中扮演什么角色。对品牌方而言,这意味着选择代理机构也需要纳入合规评估,而不只是比价。

国际合作

规划提出做好 WIPO 框架下审查业务议题磋商;推动中美欧日韩知识产权五局、金砖国家等合作机制在国际规则形成中发挥作用;与共建”一带一路”国家和地区开展审查、信息化与培训合作。

对在中国有研发或品牌布局的企业,这些机制的实际用途是判断海外申请的优先顺序:五局与金砖机制覆盖的辖区,审查实践的可比性更高,先在这些辖区布局再向外延伸,通常比平均用力更省预算。

外资研发中心的三条线

第一条是新兴领域标准。组合以人工智能、大数据或基因技术为基础的,撰写时要为”本领域技术人员”定义的调整与现有技术范围的扩大留出余地。

第二条是外观设计。图形用户界面、虚拟现实与增强现实的保护如果有意义,提交规则就是观察点,设计清单就是准备工作。

第三条是标准。企业参与标准制定的,标准必要专利审查政策与 FRAND(公平、合理、无歧视)实务要放在一起跟踪,而不是分开处理。

三条线的共同点是都需要提前准备,而不是等规则落地再动。新兴领域标准的调整会改变撰写要求,外观设计提交规则会改变申请材料,标准必要专利政策会改变许可谈判的筹码。三者都不是一年内能补上的工作。

还有一条是培训。规划要求加强国外专利审查政策公共培训及信息共享,强化海外布局能力。对中国境内的外资企业来说,这是可用资源,不是新增义务。

规划没有承诺什么

没有新设申请通道,没有承诺授权周期,也没有说某一类申请会审得更快。规划写”研究””探索”的地方,规则尚未改变。

这一条对内部沟通很重要。把方向性表述转述成”明年会更快”,会在预算与排期上造成误判;把它转述成”审查会更看重技术贡献”,才是可执行的判断。

同样需要克制的,是把”探索开展新兴领域商标注册申请预核”读成”已经可以预核”。规划用”探索”,意味着机制尚在设计中,企业按现有程序准备材料即可,不必为此调整申请节奏。

操作清单

  • 按技术贡献而非数量梳理专利组合,与高价值指标的导向对齐。
  • 人工智能相关申请,提前准备发明人署名与使用声明材料。
  • 梳理图形用户界面与外观设计资产清单,逐项跟踪提交规则。
  • 建立商标监控,维护异议与无效的时间日历。
  • 参与标准制定的,在提交贡献前统一专利与 FRAND 立场。
  • 用好审查政策公共培训与信息共享渠道。

清单的第一项最难落地,因为它要求回答”这件专利解决了什么技术问题”,而不是”今年申请了多少件”。答不上来的部分,往往就是组合里价值最低的部分。

清单也建议按主体拆分:研发负责技术贡献的说明,法务负责权利要求的层次与地域布局,品牌与市场负责商标监控。合并成一张表时,最容易暴露的是”没有人负责”的那一项。

最后一条容易被当成软性建议。但培训与信息共享恰恰是外资企业成本最低的抓手:审查政策的变化通常先在培训与通报中出现,早一步知道,就少一次返工。

展望

两份规划描述的是一个”审得更少、审得更细”的体系。对外资研发中心而言,规划要回答的问题不是申请会不会更容易,而是组合能不能用技术贡献讲清楚。

这个判断对预算有直接影响:把资源从”多申请”转向”把关键申请写扎实”,短期件数会下降,但面对审查趋严时的稳定性会提高。对以数量考核的团队,这需要提前调整考核口径,否则规划的方向与内部激励会互相抵消。

来源

  • 国家知识产权局·《专利和商标审查”十五五”规划》印发:https://www.cnipa.gov.cn/art/2026/11/3/art_53_208900.html
  • 中国政府网·《知识产权保护和运用”十五五”规划》:https://www.gov.cn/
  • 国家知识产权局:https://www.cnipa.gov.cn/
  • 国家知识产权局·知识产权保护与运用政策专栏:https://www.cnipa.gov.cn/

Plant Variety Protection: Three Rules in Force and What They Change for Breeding in China

  • Three departmental rules on plant variety protection take effect on 1 November 2026, covering the protected list, the implementing rules and the review committee.
    三件植物新品种保护配套规章于 2026 年 11 月 1 日同步施行,分别涉及保护名录、实施细则与复审委员会。
  • Plant Variety Rights now reach 308 agricultural genera and species after the twelfth batch added 117, including the sorghum genus, rye, durum wheat and Chinese chive.
    第十二批名录新增 117 个属种后,农业植物品种权保护范围扩至 308 个属种,其中包括高粱属、黑麦、硬粒小麦与香葱。
  • The implementing rules set out the steps for Essentially Derived Varieties in stages, so commercialising a modified form of a protected variety requires authorisation.
    实施细则明确了实质性派生品种制度的分步实施步骤,改良他人受保护品种后商业化需取得授权。
  • DUS Testing management and new material requirements for bio-breeding applications are added, which changes the preparation cycle and cost of a filing.
    新增 DUS 测试管理与生物育种申请材料要求,申请文件的准备周期与成本随之变化。
  • Employee Breeding now explicitly covers breeding completed within three years after retirement or transfer where it relates to the former work.
    职务育种明确涵盖退休、调离后三年内完成的与原工作有关的育种成果。
  • The review committee grows from 30 members to between 60 and 70, and its term from three years to five, widening the appeal route after a refusal.
    复审委员会由 30 名扩至 60 至 70 名,任期由三年改为五年,驳回后的救济通道因此更宽。
  • Foreign investment in seed breeding remains subject to the negative list; these rules change intellectual property protection, not market access.
    外资进入种业仍受外商投资准入负面清单约束;本轮规章改变的是知识产权保护,不是市场准入。

Plant Variety Protection: Three Rules in Force and What They Change for Breeding in China | 植物新品种保护:三项规章施行,在华育种业务改变什么

Overview

On 1 November 2026, three departmental rules of the Ministry of Agriculture and Rural Affairs took effect together: Order No. 1 of 2026 on the twelfth batch of the protected list, Order No. 2 of 2026 on the implementing rules of the Regulations on the Protection of New Plant Varieties (agricultural part), and Order No. 3 of 2026 on the review committee’s adjudication rules.

Order No. 1 was adopted at the ministry’s first executive meeting of 2026 on 28 August 2026 and promulgated by Minister Zhang Zhu on 15 September 2026. Because all three apply from the same date, one breeding programme may be touched by the list, the examination rules and the appeal procedure at once.

This refines an existing regime rather than opening a market. The Seed Law was amended in 2021, widening protection and introducing the essentially derived variety system; the State Council revised the Regulations in 2025, tightening grant conditions, extending the term and arranging phased implementation. The three rules are the operational layer beneath both.

What the implementing rules change

The official reading of Order No. 2 identifies three points.

First, it sets out the concrete steps for implementing the essentially derived variety system in stages. The concept is not new; the sequence in which it applies is what practitioners have awaited. Commercial exploitation of an essentially derived variety of a protected variety requires authorisation from the original holder.

Second, it adds DUS testing management. Distinctness, uniformity and stability testing is the technical core of any grant, and placing it in the rules raises the documentation standard.

Third, it adds material requirements for bio-breeding applications. Applicants using modern techniques should expect closer scrutiny of how the breeding process and starting material are described.

The rules also tighten grant conditions, improve examination and strengthen supervision.

The scope of protection

The scope covers new varieties of grain, cotton, oil crops, fibre crops, sugar crops, vegetables including watermelon and melon, tobacco, mulberry, tea, fruit trees other than dried fruit, ornamental plants other than woody plants, grasses, green manure, herbaceous medicinal plants, edible fungi, algae and rubber trees. A genus outside that list cannot be protected by a variety right, whatever its commercial value.

The twelfth batch

Order No. 1 adds 117 agricultural genera and species, taking the total to 308. The additions include ramie, chickpea, jute, rye, the sorghum genus, the triticale genus, durum wheat, Chinese chive including bunching onion, winter squash, water chestnut and arrowhead.

Genera outside the list can now be the subject of an application. A programme that shelved a variety because it could not be protected should revisit that decision against the new list, not against memory.

Employee breeding and the three-year lookback

The rules define employee breeding as breeding completed in the employee’s own duties, in performing a task assigned by the employer, or within three years after retirement or transfer where it relates to the former work.

The third limb catches companies out. A breeder who leaves in March and files the following year may still be producing employee breeding, and the right may belong to the former employer. Contracts covering ownership only during employment are incomplete; confidentiality, material-return and disclosure duties need to run for the same three years.

The review committee

Order No. 3 expands the review committee from 30 members to between 60 and 70 and extends the term from three years to five. It also sets out the procedure for refusals, declarations of invalidity and changes of name.

A larger committee serving longer promises no particular outcome, but the route after a refusal is better resourced and more predictable. Applicants who treated a refusal as final should reconsider.

The boundary that has not moved

None of this changes who may invest in seed breeding in China. Foreign investment in the sector remains subject to the Special Administrative Measures for Foreign Investment Access, the negative list. The rules concern intellectual property in varieties, not permission to hold or operate a breeding business.

That distinction matters internally. A joint venture reading the new rules as an opening will misjudge its approval path; one reading them as a shield for its germplasm will plan correctly.

Practical steps

  • Map every variety in the pipeline against the twelfth batch and identify those previously unprotectable.
  • Screen each candidate for essentially derived status: does it depend on a protected variety, and is authorisation in place?
  • Build DUS testing into the development calendar rather than treating it as a final step.
  • For bio-breeding applications, prepare breeding-process and material documentation in advance.
  • Rewrite breeder contracts to cover the three years after departure, with material-return and disclosure clauses.
  • Diarise refusals and appeal windows against the new committee procedure.
  • Consider variety rights alongside patents, trademarks and trade secrets for the same germplasm.

Outlook

The regime moves toward stronger protection delivered through more technical examination. Filing costs rise, and so does the value of a granted right. The competitive question shifts from whether a variety can be protected to whether the chain of derivation can be documented.

Sources

  • 农业农村部·农业农村部令 2026 年第 1 号《中华人民共和国农业植物品种保护名录(第十二批)》全文:https://nyncw.cq.gov.cn/ztzl_161/rdzt/xczx/zcwj_249776/bw_257461/202611/t20261105_16361210.html
  • 农业农村部法规司、种业管理司负责人就三项规章答问:https://www.baoan.gov.cn/bajjcj/gkmlpt/content/13/13057/post_13057320.html
  • 农业农村部·规章库(第 1/2/3 号令集中发布):https://www.moa.gov.cn/gk/nyncbgzk/
  • 中国政府网·《中华人民共和国植物新品种保护条例实施细则(农业部分)》全文(农业农村部令 2026 年第 2 号):https://www.gov.cn/zhengce/202610/content_7082787.htm

植物新品种保护:三项规章施行,在华育种业务改变什么

概述

2026 年 11 月 1 日,农业农村部三件规章同日施行:农业农村部令 2026 年第 1 号《中华人民共和国农业植物品种保护名录(第十二批)》、第 2 号《中华人民共和国植物新品种保护条例实施细则(农业部分)》、第 3 号《农业农村部植物新品种复审委员会审理规定》。

第 1 号令经 2026 年 8 月 28 日农业农村部第 1 次部务会议审议通过,由部长张柱于 2026 年 9 月 15 日发布。三件规章自同一日起适用,意味着一项育种计划现在可能同时被名录、审查规则与复审程序三方面触及。

这是对既有制度的细化,不是开放市场的举措。2021 年全国人大常委会修改种子法,扩展保护范围与保护环节、加大侵权处罚力度、建立实质性派生品种制度;2025 年国务院修订《植物新品种保护条例》,严格授权条件、优化申请授权程序、延长品种权保护期限、细化实质性派生品种制度的分步实施安排、加大侵权惩处力度。三件规章是这两部上位法之下的操作层。

读这三件规章时,有一点需要先分清:名录解决”哪些属种可以申请”,实施细则解决”按什么标准审”,复审规定解决”被驳回之后怎么救济”。三者叠加,才构成一次完整的制度变化;只看其中一件,容易高估或低估影响。

实施细则改变了什么

官方对第 2 号令的解读归纳为三点。

第一,细化实质性派生品种制度分步实施的具体步骤。概念本身不是新的,实务界等待的是它在不同情形下按什么顺序适用。当一个品种是某受保护品种的实质性派生品种时,其商业化利用需要取得原始品种权人的授权。

第二,新增 DUS 测试管理。特异性、一致性、稳定性测试是任何一次授权的技术核心,把这项管理写进规章,意味着申请人需要提供的记录材料标准提高了。

第三,新增生物育种品种权申请材料要求。使用现代育种技术的申请人,应当预期育种过程与原始材料的说明会比以往受到更细致的审查。

除这三点之外,规章同时严格授权条件、完善审查程序、强化监管。三项改动指向同一个方向:授权更审慎,材料更可核查。

三者之间不是并列关系,而是按申请流程排列:分步实施决定派生品种规则什么时候落到具体品种上,DUS 测试决定申请能不能通过,生物育种材料要求决定申请要交什么。按流程顺序读,比按条文顺序读更容易落到排期上。

保护范围

实施细则把保护范围表述为:粮食、棉花、油料、麻类、糖料、蔬菜(含西甜瓜)、烟草、桑树、茶树、果树(干果除外)、观赏植物(木本除外)、草类、绿肥、草本药材、食用菌、藻类和橡胶树等植物的新品种。

这份清单本身就是一道边界。不在清单之内的属种,无论商业价值多高,都无法取得品种权保护,唯一的路径是等待名录再增加批次。清单里两处括号也需要留意:”果树(干果除外)””观赏植物(木本除外)”,说明并非所有果树与观赏植物都在保护范围内。

实务中常见的误判,是把”在名录内”与”能授权”混为一谈。名录只是入口,能否授权还要看特异性、一致性、稳定性,以及是否属于职务育种、是否存在派生关系。

第十二批名录

第 1 号令新增 117 个农业植物属种,农业植物保护属种范围扩至 308 个。新增的属种包括罗布麻、鹰嘴豆、黄麻、黑麦、高粱属、小黑麦属、硬粒小麦、香葱(含分葱)、笋瓜(印度南瓜)、荸荠、慈姑等。

实务意义不宽,但很实在。过去落在名录之外的属种,现在可以成为申请对象。曾因无法保护而搁置某个品种的育种计划,应当对照新名录重新评估,而不是凭记忆判断。

对以加工或贸易为主的企业,这条变化同样有含义:上游供应商如果开始为某个属种申请品种权,采购合同里关于种源使用范围的约定就需要重写,否则”买了种子就能随意扩繁”的旧习惯会带来侵权风险。

另一个容易忽略的点是时间。新增属种进入名录,不等于相关品种立刻具备申请条件;育种材料的性状稳定性与测试安排仍需按实施细则准备。把名录当成”可以马上递交”的信号,往往会在测试环节返工。

职务育种与三年回溯

规章把职务育种界定为三类:在本职工作中完成的育种;履行单位交付任务完成的育种;退休、调离后三年内完成的与原工作有关的育种。

第三类容易让企业失手。一名育种人员三月离职、次年提交申请,仍可能构成职务育种,权利可能归原单位。只在在职期间约定成果归属的合同是不完整的;保密义务、材料返还义务与离职后的披露义务,至少要与同样的三年期间匹配。

实务中还有一层连带影响:交接环节。种质材料、试验记录、田间数据在人员离职时如果没有清点留档,日后主张权利时会缺少证据。三年回溯条款考验的不是合同文本,而是日常的记录管理。

从管理角度看,三年回溯把离职管理从人事问题变成了知识产权问题。研发岗位的交接清单里,除了设备与文档,还应当包括种质材料、试验编号与对外合作记录。

复审委员会

第 3 号令将复审委员会由 30 名扩至 60 至 70 名,任期由三年改为五年,并规范驳回申请复审、无效宣告与更名审理的全链条程序。

更大的委员会与更长的任期不构成对某种结果的承诺,但驳回之后的救济通道资源更充足、时限更可预期。此前把驳回视为终局的申请人,值得重新评估;把复审当作”再试一次”而非”重新论证”的做法,则不会因为委员会扩容而变得有效。

程序上的另一处变化是审理范围的完整化:驳回申请复审、无效宣告与更名三类事项被放进同一套程序规范,申请人对每一步的时限与材料可以更早预期,而不必逐案询问。

没有移动的边界

上述变化都不改变谁可以在中国投资种业。该领域的外商投资仍受《外商投资准入特别管理措施(负面清单)》约束。规章处理的是品种的知识产权保护,不是持有或经营育种业务的许可。

这一区分决定内部如何汇报。把新规读成准入开口的合资企业,会误判自己的审批路径;把它读成自有种质资源保护更厚的合资企业,规划才是对的。

换言之,负面清单决定”能不能做”,三件规章决定”做出来的成果归谁、被抄了怎么办”。两件事不能互相替代,也不能互相推导。

操作清单

  • 把在研品种清单与第十二批名录逐项比对,标出过去无法申请保护的部分。
  • 对每个候选品种做实质性派生筛查:是否依赖他人受保护品种,授权是否到位。
  • 把 DUS 测试排进研发日历,而不是当作最后的申报动作。
  • 生物育种申请,提前准备育种过程与材料说明文件。
  • 重写育种人员合同,覆盖离职后三年,并加入材料返还与披露条款。
  • 按新的复审程序,为驳回与复审时限建立日历提醒。
  • 同一份种质资源,把品种权与专利、商标、商业秘密组合考虑。

清单里最容易被跳过的是第二项。实质性派生判断依赖对他人品种的了解,而这项信息通常不在企业内部,需要专门检索与外部意见;等到申请阶段才发现派生关系,代价往往不是补交材料,而是重新设计品种。

清单本身也建议按主体拆开:研发、法务、人事各管一段,最后合并成一张表,比由单一部门统管更容易发现缺口。

展望

制度的方向是更强的保护,通过更技术的审查来实现。对育种业务而言,申请成本上升,授权权利的价值也随之上升。竞争问题从”这个品种能不能获得保护”,转向”派生链条能不能被完整记录”。

对准备在中国开展育种业务的境外企业,更现实的判断标准不是”保护变强了”,而是”自有品种在中国的权利链条能否闭合”:来源、派生、职务归属、测试记录,四项中缺一项,权利的实际价值就会打折。

来源

  • 农业农村部·农业农村部令 2026 年第 1 号《中华人民共和国农业植物品种保护名录(第十二批)》全文:https://nyncw.cq.gov.cn/ztzl_161/rdzt/xczx/zcwj_249776/bw_257461/202611/t20261105_16361210.html
  • 农业农村部法规司、种业管理司负责人就三项规章答问:https://www.baoan.gov.cn/bajjcj/gkmlpt/content/13/13057/post_13057320.html
  • 农业农村部·规章库(第 1/2/3 号令集中发布):https://www.moa.gov.cn/gk/nyncbgzk/
  • 中国政府网·《中华人民共和国植物新品种保护条例实施细则(农业部分)》全文(农业农村部令 2026 年第 2 号):https://www.gov.cn/zhengce/202610/content_7082787.htm

China’s Revised IC Layout-Design Regulation: Originality Statements and the New Filing Discipline

  • The revised Regulation on the Protection of Layout-Designs of Integrated Circuits (State Council Order No. 842) was adopted on 10 July 2026, promulgated on 23 July 2026 and took effect on 15 October 2026, in six chapters and 54 articles — the first comprehensive revision in the 25 years since the 2001 regulation.
    《集成电路布图设计保护条例》修订由国务院第 91 次常务会议于 2026 年 7 月 10 日通过,7 月 23 日以国务院令第 842 号公布,自 2026 年 10 月 15 日起施行,共 6 章 54 条,是 2001 年条例施行 25 年来第一次全面修订。
  • A statement of originality becomes a statutory filing document under Article 22, identifying the design area, design points and corresponding functions; where originality lies in the layout as a whole, Article 24 requires a specific explanation, and Article 23 requires the drawings to show the original part clearly.
    第 22 条把独创性声明列为法定登记文件,应指明独创性的设计区域、设计要点及相应功能;作为整体具有独创性的,第 24 条要求具体说明,第 23 条要求提交的图样能清楚显示独创性部分。
  • Article 20 requires an application to rest on genuine creative activity and bars falsification; Article 27 allows rejection, Article 30 lets any person request cancellation, Article 31 treats a cancelled registration as never having existed, and Article 33 adds a restoration procedure.
    第 20 条要求登记申请以真实创作活动为基础、不得弄虚作假;第 27 条规定明显不符合规定的应予驳回,第 30 条允许任何人请求撤销,第 31 条规定被撤销的专有权视为自始即不存在,第 33 条新增权利恢复程序。
  • Protection is measured by the registered copies or drawings, and the statement may be used to interpret originality (Article 34); damages follow actual loss or the infringer’s profit, and for wilful infringement in serious circumstances may be set at one to five times the amount so determined (Article 46).
    保护范围以登记的复制件或图样所显示者为准,独创性声明可用于解释独创性(第 34 条);赔偿按实际损失或侵权人获利确定,故意侵权且情节严重的,可按上述方法确定数额的 1 倍以上 5 倍以下确定(第 46 条)。
  • The term is 10 years from the filing date or from first commercial exploitation anywhere in the world, whichever is earlier, with an absolute cut-off 15 years after creation; no application filed more than two years after first commercial exploitation anywhere will be registered (Articles 17 and 26).
    保护期为 10 年,自登记申请日或世界任何地方首次商业利用之日起算,以较前日期为准;自创作完成之日起 15 年后不再保护;首次商业利用之日起 2 年内未申请登记的不再予以登记(第 17 条、第 26 条)。
  • Assignments take effect on registration, licences must be recorded within three months of the contract taking effect, pledges require registration (Article 35); a non-voluntary licence may be granted in an emergency, for public interest or to remedy a monopoly, and abuse of layout-design rights is handled under the Anti-Monopoly Law (Articles 39 and 9).
    转让自登记之日起生效,许可须在合同生效之日起 3 个月内备案,出质须办理出质登记(第 35 条);国家紧急状态、公共利益目的或经认定构成垄断需补救时可给予非自愿许可,滥用布图设计专有权依照《反垄断法》处理(第 39 条、第 9 条)。

China’s Revised IC Layout-Design Regulation: Originality Statements and the New Filing Discipline | 中国《集成电路布图设计保护条例》修订:独创性声明与登记新规

Overview

The revised Regulation on the Protection of Layout-Designs of Integrated Circuits (State Council Order No. 842) was adopted at the 91st executive meeting of the State Council on 10 July 2026, promulgated by Premier Li Qiang on 23 July 2026, and took effect on 15 October 2026. It runs to six chapters and 54 articles and is the first comprehensive revision in the 25 years since the 2001 regulation came into force. The questions and answers released with the revision set out the changes (http://mrdx.cn/content/20260804/Articel02003NR.htm).

Two changes carry most of the practical weight. A statement of originality becomes a statutory filing document, so an applicant must now say where the original design lies and what that part does. And the filing is anchored to genuine creative activity, with rejection, cancellation and restoration procedures around it. The rest of the revision modernises the term, the transaction mechanics and the remedies, and extends coverage to layouts for integrated circuits with photonic and quantum functions.

Key developments in 2026

Originality, on the record. Article 22 adds the statement of originality to the statutory filing documents, identifying the design area, the design points and the corresponding functions. Where originality lies in the layout as a whole, Article 24 requires a specific explanation to that effect. Article 23 requires the copies or drawings to show the original part clearly, so drawings and statement are prepared together.

Scope of protection. Under Article 34, protection is measured by what the registered copies or drawings show, and the statement may explain the originality. It is therefore more than a formality: it becomes an interpretive aid in infringement analysis, and a vague statement narrows the reading of the registration itself.

Filing discipline. Article 20 requires an application to rest on genuine creative activity and prohibits falsification; Article 27 provides for rejection where an application obviously fails to comply. After registration, Article 30 allows any person to request cancellation, and Article 31 treats a cancelled registration as never having existed — a retroactive consequence reaching licences and assignments already recorded. Article 33 adds a procedure for restoring rights. The Ministry of Justice’s commentary explains the statement in these terms (https://www.moj.gov.cn/pub/sfbgw/zwxxgk/fdzdgknr/fdzdgknrjdhy/202608/t20260803_538208.html).

Term and the three dates. Article 17 sets a 10-year term from the filing date or from first commercial exploitation anywhere in the world, whichever is earlier, and ends protection 15 years after creation, whether or not the layout was registered or exploited. Article 26 bars registration where no application is filed within two years of first commercial exploitation anywhere in the world.

Foreign applicants. Article 4 protects a layout created by a foreign national or enterprise where it is first commercially exploited in China, or where the applicant’s country has a protection agreement with China or is party with China to a relevant treaty. Article 5 requires a foreign applicant without habitual residence or a business office in China to appoint a patent agency established in accordance with law.

Transactions. Article 35 requires an assignment by written contract, registered and published, effective on registration; a licence by written contract, recorded within three months of the contract taking effect; a pledge by pledge registration. Article 36 lets co-owners agree how the right is exercised and supplies default rules.

Enforcement and competition. Article 46 measures damages by actual loss or the infringer’s profit, refers to a reasonable multiple of the licence fee where neither can be determined, and allows one to five times that figure for wilful infringement in serious circumstances. Articles 37 and 38 exclude copying for personal use, evaluation, analysis, research and teaching, layouts created on that basis, independent creation of an identical layout, and acts within an exhausted right. Article 39 permits a non-voluntary licence in a national emergency or other extraordinary situation, for public interest, or to remedy a monopoly found by a court or an antitrust authority. Article 9 provides that abuse of layout-design rights to exclude or restrict competition is handled under the Anti-Monopoly Law.

Practical implications for foreign businesses

The statement is a drafting project, not a form. It should be written by the engineers who know which blocks are original and why, then checked by counsel against the drawings to be filed. Because Article 34 lets the statement interpret the scope, the wording chosen at filing sets the ceiling on what can be argued later.

The genuine-creation requirement shifts attention to records: design files, revision histories, tool logs and the identity of those who did the work, which may be needed years later, particularly where a contractor or design house produced the layout. A layout supplied by a firm that did not itself create it deserves scrutiny before filing, because Article 31 reaches back over what is built on the registration.

The calendar is unforgiving. Two years from first commercial exploitation anywhere is short for a group that launches a chip abroad before considering China; ten years is the term, but fifteen years from creation is a ceiling no registration extends.

Transactions have three formal steps: an assignment signed but not registered does not transfer the right; a licence not recorded within three months leaves a compliance gap even if the contract binds the parties; a pledge needs its own registration. Co-ownership is better handled in an agreement.

Licensing now sits alongside competition law explicitly. Article 9 states the consequence, and Article 39 makes a non-voluntary licence a remedy where a monopoly is found. A programme that bundles layouts, ties licences to other products or refuses access on unexplained terms is exposed on two fronts.

Related reading

  • Patent and trademark protection for semiconductor and design businesses, and how the three regimes divide the work.
  • Merger control and antitrust review, including the treatment of intellectual property in competition analysis.
  • Technology licensing, recordal and the tax treatment of royalties paid across the border.

Sources

  • Xinhua Daily Telegraph, questions and answers with the Ministry of Justice and the intellectual property authority on the revision: http://mrdx.cn/content/20260804/Articel02003NR.htm
  • Ministry of Justice, expert commentary on the originality statement system: https://www.moj.gov.cn/pub/sfbgw/zwxxgk/fdzdgknr/fdzdgknrjdhy/202608/t20260803_538208.html
  • People’s Daily Online, reproduction of the questions and answers: https://politics.people.com.cn/BIG5/n1/2026/0803/c461001-40773140.html
  • China National Intellectual Property Administration: https://www.cnipa.gov.cn/

中国《集成电路布图设计保护条例》修订:独创性声明与登记新规

概述

《集成电路布图设计保护条例》修订经国务院第 91 次常务会议于 2026 年 7 月 10 日通过,由总理李强于 2026 年 7 月 23 日签署国务院令第 842 号公布,自 2026 年 10 月 15 日起施行。修订后的条例共 6 章 54 条,是 2001 年条例施行 25 年来第一次全面修订。随修订一同发布的答记者问,对此次修改的背景与要点作了说明(http://mrdx.cn/content/20260804/Articel02003NR.htm)。

其中两项变化承担的实务分量最重。其一,独创性声明成为法定登记文件,申请人必须说明独创性落在何处、该部分实现什么功能。其二,登记被锚定在真实创作活动之上,驳回、撤销与权利恢复程序围绕这一要求展开。其余修改则更新了保护期、权利变动的手续与救济手段,并把保护范围扩展至具有集成光子、量子等功能的集成电路布图设计。

从结构上看,这次修订没有改变布图设计专有权的取得方式——仍以登记为基础,也不改变民事保护的基本框架;改变的是登记环节要交什么、声明写什么、以及声明与保护范围之间如何对应。对已经持有登记或以许可方式使用布图设计的企业,需要重新检查的是登记档案与合同台账,而不是权利类型本身。

术语口径也需留意:条例所使用的是”布图设计””独创性””商业利用””非自愿许可”等表述,与著作权法上的”作品”、专利法上的”专利”并非同一概念。内部合规文件、供应商合同与技术许可协议在援引时,宜沿用条例用语,避免因概念混用而导致权利基础表述不准。

2026 年的关键进展

独创性,写进档案。 第 22 条把独创性声明列入法定登记文件,要求指明独创性的设计区域、设计要点及相应功能。若独创性体现为布图设计整体,第 24 条要求就此具体说明。第 23 条要求提交的复制件或图样能清楚显示独创性部分,因此图样与声明必须一并准备,而不能先出图样、后补声明。司法部发布的专家解读即按这一思路解释独创性声明制度(https://www.moj.gov.cn/pub/sfbgw/zwxxgk/fdzdgknr/fdzdgknrjdhy/202608/t20260803_538208.html)。

保护范围。 依第 34 条,保护范围以登记的复制件或图样所显示者为准,独创性声明可用于解释独创性。因此声明不只是满足形式要求:它在侵权比对中成为解释工具,写得含糊,权利人对自己已获登记的布图设计反而只能主张更窄的范围。

登记纪律。 第 20 条要求登记申请以真实创作活动为基础,不得弄虚作假;第 27 条规定,明显不符合规定的应予驳回。获准登记之后,第 30 条允许任何人请求撤销;第 31 条规定,登记被撤销的专有权视为自始即不存在——这一后果具有溯及力,会波及此前已经登记的转让与许可。第 33 条新增权利恢复程序,为耽误期限的权利人提供了一条回归路径。

保护期与三个时间点。 第 17 条规定保护期为 10 年,自登记申请日或世界任何地方首次商业利用之日起算,以较前日期为准;并规定无论是否登记或投入商业利用,自创作完成之日起 15 年后不再保护。第 26 条规定,世界任何地方首次商业利用之日起 2 年内未申请登记的不再予以登记。

外国申请人。 第 4 条规定,外国人、外国企业创作的布图设计首先在中国境内投入商业利用的,或其所属国与中国签订保护协议、共同参加有关国际条约的,依条例享有专有权。第 5 条规定,在中国没有经常居所或营业所的外国人申请登记,应当委托依法设立的专利代理机构办理。

权利变动。 第 35 条规定,转让须订立书面合同,并向主管部门登记、公告,自登记之日起生效;许可须订立书面合同,并自合同生效之日起 3 个月内备案;出质须办理出质登记。第 36 条允许共有人约定权利行使方式,未约定的适用默认规则。

救济与竞争。 第 46 条规定,赔偿按权利人的实际损失或侵权人的获利确定;两者均难以确定的,参照许可使用费的倍数合理确定;对故意侵权且情节严重的,可按上述方法确定数额的 1 倍以上 5 倍以下确定赔偿。第 37 条、第 38 条分别列出不视为侵权的情形与权利用尽:为个人目的或评价、分析、研究、教学目的复制,在评价分析基础上创作出具有独创性的布图设计,独立创作出相同布图设计,以及在权利用尽范围内的行为。第 39 条规定,国家紧急状态或非常情况、公共利益目的,或经人民法院、反垄断执法机构认定构成垄断需补救时,可以给予非自愿许可。第 9 条则明确,滥用布图设计专有权排除、限制竞争构成垄断行为的,依照《反垄断法》处理。

对外资企业的实务意义

独创性声明宜当作一项撰写工程,而不是一张表格。它应由清楚哪些模块具有独创性、理由何在的工程人员起草,再由法律顾问对照拟提交的图样核对。由于第 34 条允许以声明解释保护范围,登记时的措辞实际上设定了日后主张的上限。

真实创作的要求把注意力引向记录。设计文件、版本历史、工具日志以及实际完成人员,都是日后可能被要求出示的证据,在布图设计由承包商或设计服务公司完成的情形下尤其如此。若供应商提供的布图设计并非由其本人创作,这样的安排在申请前就值得审视,因为第 31 条的溯及后果会波及建立在登记之上的一切安排。

时间上的安排格外不容拖延。自世界任何地方首次商业利用起算的 2 年,对先在境外流片、再考虑中国市场的集团而言并不宽裕;10 年是保护期,而自创作完成起 15 年是硬性上限,任何登记都无法延长。若某款产品已在境外销售多年,宜先确认首次商业利用的具体日期,再判断是否仍有登记空间。

权利变动有三个彼此独立的手续环节。已签署但未登记的转让不产生移转效力;未在合同生效后 3 个月内备案的许可,即使合同在双方之间仍然有效,合规上仍留有缺口;出质则须单独办理出质登记。共有关系宜以协议安排,而不是留给默认规则。

许可行为现在与竞争法明确并列。第 9 条写明了后果;第 39 条则在认定垄断后把非自愿许可列为补救方式之一。把布图设计与其他产品捆绑、以许可换取其他交易条件、或以难以说明理由的条件拒绝许可的许可方案,会同时在两条线上承受压力。

对多数集团而言,真正需要动手的是三件事:核对既有登记的声明是否仍足以支撑主张的保护范围;核对许可备案、转让登记与出质登记是否齐备,尤其是跨年度、跨主体的老合同;核对尚未申请登记的布图设计是否仍落在 2 年与 15 年的窗口之内。这三项工作都不涉及重新设计产品,却直接决定一份登记在争议中能起多大作用。人民网转载的答记者问对此次修订的背景与要点亦有说明(https://politics.people.com.cn/BIG5/n1/2026/0803/c461001-40773140.html),可作为内部培训与合规宣讲的基础材料。

需要说明的是,条例自 2026 年 10 月 15 日起施行,登记实务中的具体审查尺度、声明范本与补正要求,仍以主管部门的操作口径为准。上述解读依据的是条例条文与主管部门公开发布的答记者问,不构成对个案结果的判断;具体办理仍宜与专利代理机构就声明格式与图样要求逐项核对。

延伸阅读

  • 半导体与设计企业的专利、商标保护,以及三类制度之间的分工。
  • 经营者集中审查与反垄断分析中对知识产权的处理。
  • 技术许可、备案以及跨境特许权使用费的税务处理。

来源

  • 新华每日电讯·司法部、国家知识产权局就条例修订答记者问:http://mrdx.cn/content/20260804/Articel02003NR.htm
  • 司法部·独创性声明制度专家解读:https://www.moj.gov.cn/pub/sfbgw/zwxxgk/fdzdgknr/fdzdgknrjdhy/202608/t20260803_538208.html
  • 人民网·答记者问转载:https://politics.people.com.cn/BIG5/n1/2026/0803/c461001-40773140.html
  • 国家知识产权局官网:https://www.cnipa.gov.cn/

China’s 15th Five-Year Plan Science and Technology Import Tax Incentives 2026: How Foreign R&D Centres Qualify

  • China’s Notice on Import Tax Incentives for Science and Technology during the 15th Five-Year Plan (Caiguanshui [2026] No. 7) exempts eligible institutions from import duty, import VAT and consumption tax on scientific research, technology development and teaching supplies that cannot be produced domestically or whose performance cannot meet requirements.
    中国《关于”十五五”期间支持科技创新进口税收优惠政策的通知》(财关税〔2026〕7 号)规定,对符合条件的机构进口国内不能生产或性能不能满足需要的科学研究、科技开发和教学用品,免征进口关税和进口环节增值税、消费税。
  • Foreign-invested R&D centres are expressly listed as the seventh of 13 categories of eligible entities, and are approved by the provincial commerce department together with the provincial finance and tax authorities and the local directly subordinate customs.
    外资研发中心被明确列为 13 类适用主体中的第(七)类,由省级商务主管部门会同省级财政、税务部门和所在地直属海关核定。
  • The lower half-year application window runs from 1 October to 25 October each year, with approval results released by 30 November.
    每年下半年申报窗口为 10 月 1 日至 10 月 25 日,核定结果于 11 月 30 日前发布。
  • Exempt goods are subject to list management: the list of duty-free imports is drawn up separately by the Ministry of Finance together with relevant departments, so the exemption is not automatic.
    免税进口商品实行清单管理,免税进口商品清单由财政部会同有关部门另行制定印发,因此该优惠并非自动享受。
  • A foreign-invested R&D centre that is not an independent legal person can also apply, submitting the business licence of the foreign-invested enterprise it relies on and a list of R&D investment assets.
    非独立法人的外资研发中心同样可以申报,需提交其所依托外商投资企业的营业执照以及研发总投入资产清单。

China’s 15th Five-Year Plan Science and Technology Import Tax Incentives 2026: How Foreign R&D Centres Qualify | “十五五”期间支持科技创新进口税收优惠政策 2026:外资研发中心如何符合条件

Overview

The Ministry of Finance and other departments have issued the Notice on Import Tax Incentives for Science and Technology during the 15th Five-Year Plan (Caiguanshui [2026] No. 7). The notice was made public through channels including the Anhui Regulatory Bureau of the Ministry of Finance on 12 October 2026.

The notice grants import tax exemptions to a defined set of research, education and publication institutions. Article 1 provides that scientific research institutions, technology development institutions, schools, Party schools (academies of governance) and libraries are exempt from import duty and import-stage value-added tax and consumption tax on scientific research, technology development and teaching supplies that cannot be produced domestically or whose performance cannot meet requirements. Article 2 provides that publication import units importing books and materials for scientific research and teaching for the institutions above are exempt from import-stage value-added tax.

Foreign-invested R&D centres are among the eligible entities. This article sets out the scope of the notice, the position of foreign-invested R&D centres within it, the list management requirement, and the practical steps and timing for an application.

Key developments in 2026

Thirteen categories of eligible entities

Article 3 lists the entities to which the policy applies. They are:

  1. Central, provincial and prefecture-level research institutes engaged in scientific research, and their graduate schools and libraries with independent legal person status;
  2. National laboratories and national laboratory bases;
  3. National key laboratories, national emerging industry innovation centres, national manufacturing innovation centres, national technology innovation centres, national clinical medical research centres, national industrial technology engineering centres, national university science parks, Belt and Road joint laboratories, national major science and technology infrastructure, national science and technology resource sharing platforms, and national field scientific observation and research stations;
  4. Institutions that became enterprises or entered enterprises during the reform of the science and technology system and mainly engage in scientific research and technology development;
  5. National small and medium-sized enterprise public service demonstration platforms (technology category);
  6. Enterprise technology centres recognised by the National Development and Reform Commission;
  7. Foreign-invested R&D centres approved by the provincial commerce department together with the provincial finance and tax authorities and the local directly subordinate customs;
  8. Science and technology private non-enterprise units recognised by the Ministry of Science and Technology together with the Ministry of Civil Affairs, and new-type R&D institutions of the science and technology private non-enterprise unit category approved by the provincial science and technology department together with the provincial civil affairs, finance and tax authorities and the local directly subordinate customs;
  9. Public institution-type new R&D institutions approved by the provincial science and technology department together with the provincial finance and tax authorities and the local directly subordinate customs;
  10. Higher education institutions recognised by the State that provide junior college education or above, and their branch campuses and off-site teaching institutions with independent legal person status;
  11. Party schools (academies of governance) at county level and above;
  12. Public libraries at prefecture level and above;
  13. Publication import units with publication import permits recognised by the Central Propaganda Department.

List management: the exemption is not automatic

Article 4 provides that exempt imported goods are subject to list management, and that the list of duty-free imported goods is drawn up and issued separately by the Ministry of Finance together with relevant departments. Two consequences follow: meeting the entity test is not the end of the analysis, because the specific goods must fall within the list; and because the list is issued separately, the operative scope of the exemption is set by that document rather than by the notice alone.

Article 1 also contains a substantive condition on the goods: the exemption applies to supplies that cannot be produced domestically or whose performance cannot meet requirements.

The supporting administrative measures

The Ministry of Finance, the Central Propaganda Department, the National Development and Reform Commission, the Ministry of Education, the Ministry of Science and Technology, the Ministry of Industry and Information Technology, the Ministry of Civil Affairs, the Ministry of Commerce, the Ministry of Culture and Tourism, the National Health Commission, the General Administration of Customs and the State Taxation Administration have issued the Notice on Administrative Measures for the Import Tax Incentive Policy for Science and Technology during the 15th Five-Year Plan (Caiguanshui [2026] No. 8). The administrative measures operate alongside the policy notice.

Local implementation: the Xiamen example

The Xiamen notice published on 10 October 2026 illustrates how the foreign-invested R&D centre route works in practice.

The approving authorities are the municipal commerce bureau together with the municipal finance bureau, customs and the municipal tax bureau. The approval conditions follow Annex 1 of Caiguanshui [2026] No. 8, “Conditions for Foreign-Invested R&D Centres Enjoying the Policy”.

Nine categories of application materials are required: the application form for foreign-invested R&D centres to enjoy the import tax incentive policy; an application letter covering basic information, R&D activities and a statement of conformity with the application conditions (where the centre is not an independent legal person, it must also cover the basic information of the foreign-invested enterprise it relies on); the business licence (a copy of the business licence for an independent legal person, or a copy of the business licence of the foreign-invested enterprise in which it is located for a non-independent legal person); information on total R&D investment (for an independent legal person, the foreign investment information report receipt showing the total investment amount; for a non-independent legal person, a list of total R&D investment assets, with a contract list for assets to be purchased where contracts are about to be signed); a roster of full-time research and experimental development personnel; a list of equipment cumulatively purchased since establishment (with a contract list for equipment under signed purchase contracts and due for delivery within the current year); a copy of the financial statements (or audit report) for the previous year; the most recent annual information report; and any other materials required by the approving authorities.

Applications are accepted twice a year. For the first half of the year, the window runs from 1 March to 15 March, with results released by 30 April. For the second half of the year, the window runs from 1 October to 25 October, with results released by 30 November. Additional application batches may be added where genuinely necessary.

Materials should be submitted in duplicate, in A4 format, bound in order, with the unit’s official seal on each item and a seal across the side edge.

Practical implications for foreign businesses

  • Confirm whether the centre qualifies as a foreign-invested R&D centre under Annex 1 of Caiguanshui [2026] No. 8. The policy route for a foreign-invested R&D centre is separate from the routes for domestic research institutes and universities, and the conditions in the annex are the test.
  • Plan around the second-half window of 1 October to 25 October. This is the most immediate timing point in the current batch: applications for the second half of the year close on 25 October, with results due by 30 November. Where the window has passed, the next regular opportunity is the March window, unless an additional batch is arranged.
  • Non-independent legal persons can apply. A foreign-invested R&D centre that is not an independent legal person submits the business licence of the foreign-invested enterprise it relies on and a list of total R&D investment assets. Centres that are organised as a department or branch rather than a separate company are therefore not excluded.
  • Treat the exemption as conditional on both the entity and the goods. The exemption applies to supplies that cannot be produced domestically or whose performance cannot meet requirements, and exempt goods are subject to list management with the list issued separately. The exemption should not be assumed to apply automatically to any import.
  • Assemble the nine categories of materials early. The materials span corporate documents, R&D personnel and equipment records, financial statements and information reports. Because each item must be sealed and the set bound in order, preparation time is a practical constraint.
  • Keep the approval linked to the tax and customs authorities. The approving body brings together commerce, finance, tax and customs. Aligning the application with all four reduces the risk of a gap between approval and the actual import exemption.

Related reading

  • Foreign R&D centres in China: support policies, imported research supplies and intellectual property positioning
  • The 15th Five-Year Plan and the wider incentive framework for foreign-invested R&D
  • Customs procedures for imported research and teaching supplies
  • Foreign investment information reporting for foreign-invested enterprises

Sources

  • 财政部安徽监管局·财关税〔2026〕7 号全文(含第三条 13 类主体、第四条清单管理):https://ah.mof.gov.cn/tongzhitonggao/202610/t20261012_4002591.htm
  • 厦门市商务局等四部门·外资研发中心核定条件、九类申报材料、下半年 10 月 1 日至 10 月 25 日申报窗口:https://swj.xm.gov.cn/zwgk/zfxxgk/ml/qtzfxx/202610/t20261010_3020527.htm
  • 财政部官网:https://www.mof.gov.cn/
  • 商务部官网:https://www.mofcom.gov.cn/

“十五五”期间支持科技创新进口税收优惠政策 2026:外资研发中心如何符合条件

概述

财政部等部门印发《关于”十五五”期间支持科技创新进口税收优惠政策的通知》(财关税〔2026〕7 号)。该通知于 2026 年 10 月 12 日经财政部安徽监管局等渠道公开。

通知对特定范围的科研、教育与出版机构给予进口税收优惠。第一条规定,对科学研究机构、技术开发机构、学校、党校(行政学院)、图书馆进口国内不能生产或性能不能满足需要的科学研究、科技开发和教学用品,免征进口关税和进口环节增值税、消费税。第二条规定,对出版物进口单位为上述机构进口用于科研、教学的图书、资料,免征进口环节增值税。

外资研发中心属于适用主体之一。本文梳理通知的适用范围、外资研发中心在其中的位置、清单管理要求,以及申报的实务步骤与时间安排。

2026 年主要进展

十三类适用主体

第三条规定了政策适用的主体范围:

  1. 从事科学研究工作的中央级、省级、地市级科研院所及其具有独立法人资格的研究生院、图书馆;
  2. 国家实验室、国家实验室基地;
  3. 全国重点实验室、国家新兴产业创新中心、国家制造业创新中心、国家技术创新中心、国家临床医学研究中心、国家产业技术工程化中心、国家大学科技园、”一带一路”联合实验室、国家重大科技基础设施、国家科技资源共享服务平台、国家野外科学观测研究站;
  4. 科技体制改革过程中转制为企业和进入企业的主要从事科学研究、技术开发工作的机构;
  5. 国家中小企业公共服务示范平台(技术类);
  6. 国家发展改革委企业技术中心;
  7. 省级商务主管部门会同省级财政、税务部门和所在地直属海关核定的外资研发中心;
  8. 科技部会同民政部核定的科技类民办非企业单位,省级科技主管部门会同省级民政、财政、税务部门和所在地直属海关核定的科技类民办非企业单位类新型研发机构;
  9. 省级科技主管部门会同省级财政、税务部门和所在地直属海关核定的事业单位类新型研发机构;
  10. 国家承认学历的实施专科及以上高等学历教育的高等学校及其具有独立法人资格的分校、异地办学机构;
  11. 县级及以上党校(行政学院);
  12. 地市级及以上公共图书馆;
  13. 中央宣传部核定的具有出版物进口许可的出版物进口单位。

清单管理:优惠并非自动享受

第四条规定,免税进口商品实行清单管理,免税进口商品清单由财政部会同有关部门另行制定印发。由此产生两点实务后果。其一,符合主体条件并不等于分析结束,具体商品还须落在清单范围内。其二,由于清单另行印发,免税的实际适用范围由该清单确定,而不仅由通知本身确定。

第一条还对商品本身设定了实质条件:免税适用于国内不能生产或性能不能满足需要的用品。这一条件与清单要求并列存在。

配套管理办法

财政部、中央宣传部、国家发展改革委、教育部、科技部、工业和信息化部、民政部、商务部、文化和旅游部、国家卫生健康委、海关总署、税务总局印发《关于”十五五”期间支持科技创新进口税收优惠政策管理办法的通知》(财关税〔2026〕8 号)。管理办法与政策通知配套执行。

地方落实:厦门范例

厦门市 2026 年 10 月 10 日发布的通知,展示了外资研发中心这一路径的实际操作方式。

核定部门为市商务局会同市财政局、海关、市税务局。核定条件按财关税〔2026〕8 号附件 1″享受政策的外资研发中心条件”执行。

申报材料共九类:外资研发中心享受进口税收优惠政策申报表;申请书(含基本情况、研发活动情况、符合申报条件的说明;属非独立法人的,还应包括所依托外商投资企业基本情况);营业执照(独立法人提交营业执照复印件,非独立法人提交其所在外商投资企业营业执照复印件);研发总投入情况(独立法人提供载有投资总额的外商投资信息报告回执;非独立法人提供研发总投入资产清单,即将投入并签订购置合同的资产应提交即将采购资产的合同清单);专职研究与试验发展人员名册;设立以来累计购置的设备清单(已签订购置合同并于当年内交货的设备应同时提交合同清单);上一年度财务报表(或审计报告)复印件;最近一期的年度信息报告书;审核部门要求的其他材料。

申报每年开展两次。上半年为 3 月 1 日至 3 月 15 日,核定结果于 4 月 30 日前发布;下半年为 10 月 1 日至 10 月 25 日,核定结果于 11 月 30 日前发布。如确有必要,可增加申报批次。

材料要求为一式二份,A4 规格,按顺序装订成册,每项材料加盖单位公章,并在侧面骑缝加盖公章。

对外资企业的实务意义

  • 先确认研发中心是否符合财关税〔2026〕8 号附件 1 的条件。 外资研发中心的政策路径与国内科研院所、高校的路径相互独立,附件所列条件即为判定标准。
  • 围绕 10 月 1 日至 10 月 25 日的下半年窗口安排时间。 这是本批次最直接的时间节点:下半年申报于 10 月 25 日截止,核定结果于 11 月 30 日前发布。若窗口已过,下一次常规机会为次年 3 月窗口,除非另行增加批次。
  • 非独立法人也可申报。 非独立法人的外资研发中心提交其所依托外商投资企业的营业执照以及研发总投入资产清单。以部门或分支机构形式而非独立公司形式设立的中心,并不因此被排除在外。
  • 把优惠理解为”主体 + 商品”双重条件。 免税适用于国内不能生产或性能不能满足需要的用品,且免税商品实行清单管理、清单另行印发。不应假定任何进口都自动适用免税。
  • 尽早准备九类材料。 材料涉及企业证照、研发人员与设备记录、财务报表与信息报告等。由于每项材料均须盖章并按顺序装订,准备周期是一项现实约束。
  • 让核定与税务、海关环节保持衔接。 核定部门由商务、财政、税务与海关共同组成。在申报阶段同步对接四方,可降低核定通过后与实际进口免税之间的落差风险。

相关阅读

  • 外资研发中心在华:支持政策、进口科研用品与知识产权布局
  • “十五五”规划与外资研发中心更广泛的优惠框架
  • 进口科研与教学用品的海关流程
  • 外商投资企业的外商投资信息报告

来源

  • 财政部安徽监管局·财关税〔2026〕7 号全文(含第三条 13 类主体、第四条清单管理):https://ah.mof.gov.cn/tongzhitonggao/202610/t20261012_4002591.htm
  • 厦门市商务局等四部门·外资研发中心核定条件、九类申报材料、下半年 10 月 1 日至 10 月 25 日申报窗口:https://swj.xm.gov.cn/zwgk/zfxxgk/ml/qtzfxx/202610/t20261010_3020527.htm
  • 财政部官网:https://www.mof.gov.cn/
  • 商务部官网:https://www.mofcom.gov.cn/

CNIPA and GACC Joint Opinion 2026: Strengthened IPR Customs Protection for Trademark and Patent Owners

  • On 8 October 2026 the China National Intellectual Property Administration and the General Administration of Customs jointly issued the Opinions on Strengthening Coordinated Intellectual Property Protection, released publicly on 14 October.
    2026 年 10 月 8 日,国家知识产权局与海关总署联合印发《关于强化知识产权协同保护的意见》,并于 10 月 14 日公开发布。
  • The Opinions set out seven areas of work, covering information sharing, investigation assistance, business support, key-sector protection, joint research, talent development and evaluation.
    《意见》提出七项重点工作,涵盖信息共享、调查协助、业务支撑、重点领域保护、会商调研、人才培养和评估奖惩。
  • Under information sharing, CNIPA will provide customs with trademark and patent basic data on a regular basis to make it easier for rights holders to complete customs recordation.
    在信息共享方面,国家知识产权局将定期向海关总署提供商标、专利等基础数据信息,便利权利人办理海关备案。
  • The two authorities will also share well-known trademark confirmations, records of revoked or invalidated trademarks, and decisions in major patent infringement administrative rulings.
    双方还将共享驰名商标确认信息、撤销或者宣告无效的商标信息,以及重大专利侵权纠纷行政裁决决定信息。
  • For patent cases involving technical questions, CNIPA will recommend experts such as technical investigation officers to customs according to customs needs.
    对涉及专业技术性事项的专利侵权案件,国家知识产权局将根据海关需求推荐技术调查官等专家。
  • The Opinions encourage rights holders with well-known trademark records, collective or certification marks registered as geographical indications, and photovoltaic and other key industry enterprises to file customs recordation.
    《意见》鼓励有驰名商标确认记录、作为地理标志注册的集体商标或证明商标,以及光伏等重点产业企业的权利人积极向海关申请知识产权备案。
  • The customs recordation system itself already exists; the Opinions strengthen coordination around it rather than creating a new recordation regime.
    海关知识产权备案制度本身早已存在;《意见》是在其基础上强化协同,而非新设一项备案制度。
  • Implementation is led by the IP Protection Department of CNIPA and the Comprehensive Business Department of GACC, which will establish a standing liaison mechanism with designated contacts.
    落实工作由国家知识产权局知识产权保护司与海关总署综合业务司牵头,建立常态化联络机制并确定联络人。

CNIPA and GACC Joint Opinion 2026: Strengthened IPR Customs Protection for Trademark and Patent Owners | 国家知识产权局与海关总署 2026 年联合意见:商标与专利权利人的知识产权海关保护协同

Overview

On 8 October 2026, the China National Intellectual Property Administration (CNIPA) and the General Administration of Customs (GACC) jointly issued the Opinions on Strengthening Coordinated Intellectual Property Protection (《关于强化知识产权协同保护的意见》). The document was released publicly on 14 October 2026.

The stated aim is to combine the strengths of the intellectual property administration and customs so that the two work as one force, advance protection across the whole intellectual property chain, and support a sound business and innovation environment. For trademark and patent owners, the practical question is what the coordination changes at the border and in the recordation process, and what it does not change. This article sets out the seven areas of work, reproduces the official wording where it matters, and identifies the practical handles for foreign rights holders. It does not extend the text beyond what the document says.

Key developments in 2026

The Opinions are organised into seven areas of work, together with implementation arrangements.

Information sharing. The two authorities will establish a long-term working mechanism for data sharing and application. CNIPA will provide GACC with trademark and patent basic data on a regular basis, which makes it easier for rights holders to complete customs recordation. The two will also share well-known trademark confirmation information, information on trademarks that have been revoked or declared invalid, and decisions in major patent infringement administrative dispute rulings, to assist customs enforcement. GACC will provide CNIPA with data on trademarks and patents that have been recorded for customs protection and on trademark and patent cases in which goods have been confiscated. The two will notify each other of their administrative enforcement replies in trademark and patent matters, to promote consistency in infringement assessment standards, and will jointly advance intellectual property informatisation.

Investigation assistance. Where the intellectual property administration handles a trademark or patent infringement case involving imported or exported goods and requests customs assistance, customs is to provide it. Where customs investigates suspected infringing goods that have been detained and requests assistance, the intellectual property administration is to assist. For patent infringement cases involving specialised technical matters, CNIPA will recommend experts such as technical investigation officers according to customs needs. Verification of registered trademark information and status may be carried out through the CNIPA trademark registration certificate public notice system.

Business support. When customs investigates goods suspected of infringing trademark or patent rights, it will refer fully to the infringement assessment standards formulated by CNIPA as well as to relevant administrative replies and administrative ruling decisions made by the intellectual property administration. For relatively specialised and complex questions of identification — the same goods, similar goods, identical trademarks, similar trademarks and patent infringement — customs may seek the views of the intellectual property administration at the same level, which is to reply in a timely manner and issue a professional opinion.

Key-sector protection. The intellectual property administration encourages rights holders with well-known trademark confirmation records, collective or certification marks registered as geographical indications, and photovoltaic and other key industry enterprises to actively apply to customs for intellectual property recordation. GACC reviews applications in accordance with the law, and once recordation is completed, customs strengthens protection based on national industrial policy and the results of risk analysis.

Joint research, talent and evaluation. The two will hold discussions on difficult trademark and patent cases, conduct joint research on major difficult issues to promote consistency in enforcement standards, and jointly advance the use of new technologies such as artificial intelligence and big data in intellectual property protection. They will exchange teaching resources and support specialised training on foreign-related intellectual property protection. They will periodically evaluate the effectiveness of protection work, publicly commend outstanding collectives and individuals, and remind those whose work is lagging.

Implementation. The work is led by the IP Protection Department of CNIPA and the Comprehensive Business Department of GACC, which will establish a standing liaison mechanism and designate contacts. Intellectual property administration departments below the provincial level and customs offices directly under GACC will establish corresponding liaison mechanisms.

Practical implications for foreign businesses

Five practical handles follow for foreign trademark and patent owners.

First, recordation remains the core instrument. Customs active protection applies to trademarks and patents that have been recorded; the Opinions reinforce the recordation process rather than replace it. The information-sharing measures are designed to make recordation easier to complete.

Second, certain categories of rights holders are explicitly encouraged to apply for recordation: those with well-known trademark confirmation records, collective or certification marks registered as geographical indications, and photovoltaic and other key industry enterprises. Once recorded, customs strengthens protection based on national industrial policy and risk analysis.

Third, technical investigation officers now enter the customs case-support system. For patent matters, where the technical questions are specialised, CNIPA may recommend experts such as technical investigation officers according to customs needs, so patent infringement assessment does not rest on customs judgement alone.

Fourth, consistency of infringement assessment standards improves predictability. Customs refers to CNIPA’s infringement assessment standards and to administrative replies and rulings, and may consult the intellectual property administration at the same level on difficult identification questions.

Fifth, specialised training on foreign-related intellectual property protection is written into the document, indicating a direction of professionalisation in cross-border enforcement.

One clarification belongs in any complete reading. The Opinions do not create a new recordation regime. Customs intellectual property recordation has long existed under the applicable customs rules. What the Opinions do is strengthen coordination around that existing framework — through data sharing, investigation assistance, standard alignment and key-sector encouragement — so that the two authorities act with a common understanding. Rights holders who already hold recordation, and those considering it, should read the document as an improvement in the operating environment for enforcement at the border.

Related reading

  • Customs intellectual property recordation is the gateway to customs active protection for recorded trademarks and patents.
  • For patent cases involving specialised technical matters, CNIPA may recommend experts such as technical investigation officers to customs.
  • Rights holders with well-known trademark records, geographical indication collective or certification marks, and photovoltaic and other key industry enterprises are encouraged to apply for recordation.

Sources

  • 国家知识产权局官网·《关于强化知识产权协同保护的意见》全文:https://www.cnipa.gov.cn/art/2026/10/14/art_3611_208509.html?xxgkhide=1
  • 中国金融新闻网·两部门联合印发及七项重点工作全文(2026-10-14):https://www.financialnews.com.cn/2026-10/14/content_458807.html
  • 新华报业网转央视·重点领域保护报道:https://www.xhby.net/content/s6acf29f1e4b0cd8a37594433.html
  • 海关总署官网(海关知识产权保护相关公告与政策栏目):http://www.customs.gov.cn/

国家知识产权局与海关总署 2026 年联合意见:商标与专利权利人的知识产权海关保护协同

概述

2026 年 10 月 8 日,国家知识产权局与海关总署联合印发《关于强化知识产权协同保护的意见》,并于 2026 年 10 月 14 日公开发布。

《意见》的目标是发挥知识产权管理部门与海关的各自优势,形成工作合力,协同推进知识产权全链条保护,营造良好营商环境和创新环境。对商标与专利权利人而言,实务问题在于:这一协同在口岸环节与备案流程中改变了什么,又没有改变什么。本文梳理《意见》的七项重点工作,在关键处照录官方原文表述,并指出外资权利人的实操抓手。本文不超出文件本身所写的内容作延伸。

2026 年的关键进展

《意见》分为七项重点工作,并配有落实安排。

加强信息共享。 双方将建立数据共享应用合作长效工作机制。国家知识产权局定期向海关总署提供商标、专利等基础数据信息,便利权利人办理海关备案;同时共享驰名商标确认信息、撤销或者宣告无效的商标信息,以及重大专利侵权纠纷行政裁决决定信息,辅助海关执法。海关总署定期向国家知识产权局提供进行海关保护备案的商标、专利数据信息,以及予以没收的商标、专利案件信息。双方互相通报各自作出的商标、专利行政执法答复,促进商标、专利侵权判断标准统一,并共同推动知识产权信息化建设。

强化调查协助。 知识产权管理部门处理涉及进出口货物的商标、专利侵权案件请求海关协助的,海关应当予以协助;海关对被扣留的侵权嫌疑货物进行调查请求协助的,知识产权管理部门应当协助。对涉及专业技术性事项的专利侵权案件,国家知识产权局将根据海关需求推荐技术调查官等专家。核实注册商标信息及状态,可通过国家知识产权局商标注册证明公示系统进行。

加强业务支撑。 海关调查涉嫌侵犯商标权、专利权的货物时,充分参考国家知识产权局制定的侵权判断标准,以及知识产权管理部门作出的相关行政答复、行政裁决决定;遇较专业复杂的同一种商品、类似商品、相同商标、近似商标、专利侵权等认定问题,可征求同级知识产权管理部门意见,知识产权管理部门应及时答复、出具专业意见。

强化重点领域保护。 知识产权管理部门鼓励有驰名商标确认记录、作为地理标志注册的集体商标或证明商标,以及光伏等重点产业企业的权利人,积极向海关申请知识产权备案。海关总署依法审核;经海关总署备案后,海关基于国家产业政策和风险分析结果加强保护。

加强会商调研、人才培养和评估奖惩。 双方就商标、专利疑难案件开展研讨,对重大疑难问题联合调研,促进执法标准统一;共同推进人工智能、大数据等新技术在知识产权保护工作中的应用。互派师资,支持涉外知识产权保护专业培训。定期评估保护工作成效,对突出集体和个人通报表扬,对工作不力的督促提醒。

落实安排。 工作由国家知识产权局知识产权保护司与海关总署综合业务司牵头,建立常态化联络机制、确定联络人;省级以下知识产权管理部门、直属海关建立相应联络机制。

对外资企业的实务意义

对外资商标与专利权利人而言,有五个实操抓手。

第一,备案仍是核心抓手。海关的主动保护适用于已备案的商标与专利;《意见》强化的是围绕备案流程的协同,而非取而代之。信息共享方面的举措,目的在于让备案更便于完成。

第二,若干类权利人被明确鼓励申请备案:有驰名商标确认记录的、作为地理标志注册的集体商标或证明商标的,以及光伏等重点产业企业的权利人。备案完成后,海关基于国家产业政策和风险分析结果加强保护。

第三,技术调查官进入海关办案支持体系。就专利事项而言,遇专业技术性较强的问题,国家知识产权局可根据海关需求推荐技术调查官等专家,专利侵权认定不再只依赖海关自身判断。

第四,侵权判断标准趋于统一,可预期性提升。海关参考国家知识产权局的侵权判断标准及相关行政答复、裁决,遇疑难认定问题还可征求同级知识产权管理部门意见。

第五,涉外知识产权保护专业培训被写入文件,指向跨境维权的专业化方向。

任何完整的解读都应包含一处澄清。《意见》并未新设一项备案制度。海关知识产权备案制度早已存在,其依据是适用的海关规则。《意见》所做的是围绕这一既有框架强化协同——通过数据共享、调查协助、标准衔接与重点领域鼓励,使两个部门以一致理解开展工作。已持有备案的权利人,以及正在考虑备案的权利人,宜将该文件理解为口岸执法营商环境的改善。

延伸阅读

  • 海关知识产权备案,是已备案商标与专利获得海关主动保护的前提。
  • 对涉及专业技术性事项的专利侵权案件,国家知识产权局可根据海关需求推荐技术调查官等专家。
  • 有驰名商标确认记录、作为地理标志注册的集体商标或证明商标,以及光伏等重点产业企业的权利人,被鼓励申请备案。

来源

  • 国家知识产权局官网·《关于强化知识产权协同保护的意见》全文:https://www.cnipa.gov.cn/art/2026/10/14/art_3611_208509.html?xxgkhide=1
  • 中国金融新闻网·两部门联合印发及七项重点工作全文(2026-10-14):https://www.financialnews.com.cn/2026-10/14/content_458807.html
  • 新华报业网转央视·重点领域保护报道:https://www.xhby.net/content/s6acf29f1e4b0cd8a37594433.html
  • 海关总署官网(海关知识产权保护相关公告与政策栏目):http://www.customs.gov.cn/

Brain-computer interface medical devices: China’s innovative registration policy direction

  • At the 2026 International Biomedical Industry Innovation Beijing Forum in Yizhuang, an official from the NMPA Medical Device Registration Management Department said brain-computer interface (BCI) has been incorporated into China’s 15th Five-Year Plan and written into the Government Work Report, and is positioned as a future industry.
    在2026国际生物医药产业创新北京论坛(北京亦庄)”神经调控与脑机接口技术产业发展论坛”上,国家药监局医疗器械注册管理司相关负责人表示,脑机接口已被纳入我国”十五五”规划、写入政府工作报告,明确作为未来产业予以布局。
  • The regulator signalled that supporting innovative registration and management policies will be introduced to systematically support the development and translation of BCI medical devices.
    药监部门表示将配套创新注册管理政策,系统支持脑机接口医疗器械的研发与落地转化。
  • As of end-July 2026, China had more than 347,000 valid medical-device registrations and filings; in 2025 the NMPA approved 14,187 medical-device registrations, up 8 per cent year on year.
    截至2026年7月底,全国有效医疗器械注册备案产品超过34.7万件;2025年国家药监局共批准医疗器械注册14187项,同比增长8%。
  • The “Spring Rain Action” clinical-translation programme has collected more than 400 Class III medical-device products and placed 22 quality projects into an expedited pre-review green channel.
    医疗器械临床创新成果转化”春雨行动”已征集400多个三类医疗器械产品,已有22个优质项目纳入审评前置绿色通道。
  • On standards, three industry standards for BCI have been issued, ten national standards and three industry standards are under development, and one international-standard proposal has been submitted, covering EEG acquisition, signal transmission, motor-intention decoding and device reliability.
    在标准方面,脑机接口领域已累计发布3项行业标准,立项10项国家标准、3项行业标准,并提交1项国际标准立项提案,覆盖脑电采集、信号传输、运动意图解码与设备可靠性等核心技术环节。
  • The regulator describes its approach as “front-loading regulation and standards first”, including pre-application technical guidance for both invasive and non-invasive products and unified naming and classification rules.
    监管方式被概括为”监管前置、标准先行”,包括对多款侵入式、非侵入式产品开展前置技术指导,并统一产品命名与分类界定规则。
  • For foreign companies the practical relevance is analytical rather than a formal commitment: the policy direction points to clearer registration pathways, but no specific BCI approval timelines, acceptance numbers or product names have been published.
    对境外企业而言,其实际意义属分析性判断而非官方承诺:政策方向指向更清晰的注册路径,但截至目前并未公布具体的脑机接口审批时限、受理编号或产品名称。

Brain-computer interface medical devices: China’s innovative registration policy direction | 脑机接口医疗器械:中国创新注册管理政策方向

Overview

In October 2026, the 2026 International Biomedical Industry Innovation Beijing Forum was held in Yizhuang, Beijing. At the forum’s “Neuromodulation and Brain-Computer Interface Technology Industry Development Forum”, an official from the Medical Device Registration Management Department of the National Medical Products Administration (NMPA) set out the regulator’s current reading of brain-computer interface (BCI) medical devices and the registration policy direction attached to them.

According to the remarks, BCI has been incorporated into China’s 15th Five-Year Plan and written into the Government Work Report, and is expressly positioned as a future industry. On that basis, the regulator said it would put in place supporting innovative registration and management policies to systematically support the research, development and translation of BCI medical devices.

The remarks are a policy-direction statement rather than a new rule. They describe how the existing medical-device registration system is being oriented towards BCI, and they rest on a set of published industry figures that show how the registration base and the innovation-support toolkit have grown.

Key developments

The official’s remarks combined a positioning statement with concrete numbers on China’s medical-device registration landscape.

  • Registration base. As of end-July 2026, China had more than 347,000 valid medical-device registrations and filings, spanning Class III registration certificates, Class II registration certificates and Class I filings.
  • Annual approvals. In 2025, the NMPA approved 14,187 medical-device registrations, an increase of 8 per cent year on year.
  • Clinical translation programme. The “Spring Rain Action” for the translation of clinical innovations in medical devices had collected more than 400 Class III medical-device products, covering high-end tracks such as BCI, interventional surgical robots, AI diagnostic software and high-end interventional implants and biomaterials. 22 quality projects had been placed into an expedited pre-review green channel.

Read together, these figures describe a large and still-growing registration pipeline, and a deliberate effort to move selected high-end products through review faster than the ordinary queue.

Standards first: the pre-review and standards toolkit

Alongside the registration figures, the remarks described the regulator’s operating approach as “front-loading regulation and standards first”.

On standards, the BCI field has seen:

  • three industry standards issued;
  • ten national standards and three industry standards initiated (立项); and
  • one international-standard proposal submitted.

The published standards cover core technical links including EEG acquisition, signal transmission, motor-intention decoding and device reliability.

On regulation, the approach includes:

  • advance planning of regulatory-science research;
  • pre-application technical guidance for a number of both invasive and non-invasive products; and
  • unified rules for product naming and classification.

The “standards first” logic matters for a technology like BCI, where the boundary between a medical device, a consumer wearable and a research instrument can be genuinely unclear. Naming and classification rules, and the existence of standards for core components, are the practical preconditions for a device to move into a defined registration pathway.

Next steps in regulation

The official set out the next steps in general terms: continuing to deepen reform of the medical-device review and approval system and to increase support for high-end innovative devices. Specific measures mentioned included:

  • optimising the review mechanism for “globally new” products;
  • providing front-loaded services such as clinical-trial pre-review and technical consultation; and
  • thereby accelerating the market launch of landmark products.

These are direction statements. They indicate where the regulator intends to concentrate facilitation effort, not the terms on which any individual product will be reviewed.

Practical implications for foreign companies

The following points are analytical observations, not official commitments. They describe what the policy direction may mean for foreign BCI and neurotechnology companies considering the China market.

  • The direction of travel is clearer, the details are not. A stated intent to build supporting innovative registration policies for BCI signals that the regulator is treating the field as a priority. It does not, on its own, change any filing requirement, and no BCI-specific approval timeline, acceptance number or product name has been published.
  • Classification and naming are the first practical questions. Because the regulator is unifying naming and classification rules for BCI, a company’s early task is to understand how its product would be classified and named under the Chinese system, since that determines the registration pathway.
  • Standards participation is a defined channel. With national and industry standards under development and an international-standard proposal submitted, there is an active standards-setting process. Foreign companies commonly monitor or participate in such processes through their China entities or industry associations, though the terms of participation follow the applicable standards rules.
  • Patent and intellectual-property positioning deserves early attention. BCI spans hardware, signal-processing algorithms and software. Companies usually review how their patent portfolio maps onto the Chinese classification and standards landscape before committing to a registration strategy. This is a commercial and legal planning point, not a statement of any regulatory preference.
  • Translation programmes are a signal, not a guarantee. The “Spring Rain Action” pipeline shows that a subset of high-end products is being routed into an expedited pre-review channel. Being in a high-priority field is relevant context, but selection for such programmes is a separate process.

Related considerations

For a foreign company, the sensible reading of these remarks is as a map of the regulator’s priorities rather than a set of entitlements. The registration figures show scale; the standards activity shows the field maturing towards defined technical requirements; and the “front-loading” language shows where facilitation effort is being directed. A company planning a China BCI strategy would typically combine this policy context with a product-specific review of classification, standards alignment, patent position and the appropriate registration pathway, and would confirm current requirements against the latest official publications before relying on any particular route.

Sources

  • 经济参考报 2026-10-08 报道(环球医药网转载)— 脑机接口纳入”十五五”规划与创新注册管理政策表态: https://www.qgyyzs.net/news/newshtml/hyxx/20261008090946.shtml
  • 中国政府网 — 未来产业与”十五五”规划政策背景: https://www.gov.cn/yaowen/liebiao/202610/content_7082824.htm
  • 中国网(受权发布)— 《关于发展新质生产力的意见》全文(含”前瞻布局未来产业”等产业定位表述): https://big5.china.com.cn/gate/big5/news.china.com.cn/2026-10/10/content_118727382.shtml

脑机接口医疗器械:中国创新注册管理政策方向

概述

2026年10月,2026国际生物医药产业创新北京论坛在北京亦庄举行。在该论坛的”神经调控与脑机接口技术产业发展论坛”上,国家药品监督管理局医疗器械注册管理司相关负责人就脑机接口医疗器械的监管现状与注册政策方向作了介绍。

据该负责人介绍,脑机接口已被纳入我国“十五五”规划、写入政府工作报告,明确作为未来产业予以布局。在此基础上,药监部门表示将配套创新注册管理政策,系统支持脑机接口医疗器械的研发与落地转化。

上述表态属政策方向性说明,而非新出台的规则。它描述的是现行医疗器械注册体系正如何向脑机接口领域倾斜,并以一组已公布的行业数据为依托,展示注册基数与创新支持工具的发展情况。

主要进展

该负责人的介绍将产业定位与具体数据结合在一起,勾勒出我国医疗器械注册的整体面貌。

  • 注册基数。 截至2026年7月底,全国有效医疗器械注册备案产品超过34.7万件,涵盖三类注册证、二类注册证及一类备案产品。
  • 年度批准量。 2025年,国家药监局共批准医疗器械注册14187项,同比增长8%。
  • 临床转化项目。 医疗器械临床创新成果转化“春雨行动”已征集400多个三类医疗器械产品,覆盖脑机接口、介入手术机器人、人工智能诊疗软件、高端植介入生物材料等高端赛道;已有22个优质项目纳入审评前置绿色通道。

综合来看,这组数据一方面说明注册管线规模庞大且仍在增长,另一方面也说明监管机构有意让部分高端产品以快于常规队列的方式通过审评。

标准先行:前置审评与标准工具箱

在注册数据之外,该负责人将监管机构的运行思路概括为“监管前置、标准先行”。

在标准方面,脑机接口领域已实现:

  • 累计发布3项行业标准;
  • 立项10项国家标准、3项行业标准;
  • 提交1项国际标准立项提案。

已发布的标准覆盖脑电采集、信号传输、运动意图解码、设备可靠性等核心技术环节。

在监管方面,相关做法包括:

  • 提前布局监管科学研究;
  • 对多款侵入式、非侵入式产品开展前置技术指导;
  • 统一产品命名与分类界定规则。

“标准先行”的逻辑对脑机接口这类技术尤为重要——医疗器械、消费级可穿戴设备与研究仪器之间的边界有时并不清晰。命名与分类界定规则,以及核心部件标准的建立,是产品得以进入明确注册路径的现实前提。

下一步监管方向

该负责人以总体表述方式提出了下一步方向:持续深化医疗器械审评审批制度改革,持续加大高端创新器械扶持力度。其中提到的具体举措包括:

  • 优化”全球新”产品审评机制;
  • 提供临床试验预审、技术咨询等前置服务;
  • 进而加速标杆产品上市。

这些属方向性表述,指示监管机构拟在何处集中便利化资源,并不等同于任何单一产品的审评条件。

对境外企业的实务意义

以下要点为分析性观察,并非官方承诺。它们描述的是该政策方向对考虑进入中国市场的境外脑机接口与神经技术企业可能意味着什么。

  • 方向更清晰,细节尚未明确。 表态提出将为脑机接口构建配套创新注册政策,说明监管机构将该领域视为优先方向。但这一表态本身并不改变任何申报要求,且截至目前并未公布脑机接口专属的审批时限、受理编号或产品名称。
  • 分类与命名是首要实务问题。 由于监管机构正在统一脑机接口的命名与分类界定规则,企业的早期工作之一是弄清其产品在中国体系下将被如何分类与命名,因为这决定了注册路径。
  • 参与标准化是一条既有通道。 随着国家标准与行业标准在研、国际标准提案已提交,标准化进程处于活跃状态。境外企业通常通过其在华主体或行业协会关注或参与此类进程,但参与条件须遵循适用的标准化管理规定。
  • 专利与知识产权布局宜及早关注。 脑机接口横跨硬件、信号处理算法与软件。企业通常会在确定注册策略前,先梳理其专利组合如何对应中国的分类与标准格局。这属商业与法律规划事项,并非监管倾向性表述。
  • 转化项目是信号,而非保证。 “春雨行动”管线显示,部分高端产品正被纳入审评前置快速通道。身处高优先级领域是相关背景,但能否入选此类项目是另一套独立程序。

相关考量

对境外企业而言,将上述表态理解为监管机构优先事项的路线图,比理解为一系列既得权益更为妥当。注册数据体现规模,标准化活动体现该领域正走向明确的技术要求,”前置”表述则体现便利化资源投入的方向。规划中国脑机接口战略的企业,通常会将这一政策背景与针对具体产品的分类、标准对齐、专利布局及相应注册路径评估结合起来,并在依赖任何具体路径前,依据最新官方发布确认现行要求。

来源

  • 经济参考报 2026-10-08 报道(环球医药网转载)— 脑机接口纳入”十五五”规划与创新注册管理政策表态: https://www.qgyyzs.net/news/newshtml/hyxx/20261008090946.shtml
  • 中国政府网 — 未来产业与”十五五”规划政策背景: https://www.gov.cn/yaowen/liebiao/202610/content_7082824.htm
  • 中国网(受权发布)— 《关于发展新质生产力的意见》全文(含”前瞻布局未来产业”等产业定位表述): https://big5.china.com.cn/gate/big5/news.china.com.cn/2026-10/10/content_118727382.shtml

Traditional Chinese Medicine Knowledge Protection: What the September 2026 Draft Regulation Means for Foreign Pharmaceutical and Healthcare Companies

  • On 18 September 2026, the State Council executive meeting reviewed and approved in principle the Draft Regulation on the Protection of Traditional Chinese Medicine Knowledge, describing traditional Chinese medicine theory, techniques and formulas as important resources for China’s own innovation and calling for comprehensive strengthening of protection and management.
    2026年9月18日,国务院常务会议审议通过《中医药传统知识保护条例(草案)》,会议指出中医药理论、技术和方药是我国自主创新的重要资源,要全面加强保护管理。
  • The regulation is to establish a protection system for traditional Chinese medicine knowledge: after registration and review-based recognition, a holder enjoys rights to indicate identity, to transmit and use, to informed consent, to benefit sharing, to integrity protection and to require disclosure of source, while medical institutions are encouraged to proactively investigate and develop proven formulas, secret formulas and techniques.
    条例将建立中医药传统知识保护制度:经登记并审核认定后,持有人享有表明身份、传承使用、知情同意、利益分享、完整保护、要求说明来源等权利,并鼓励医疗机构主动调查发现中医药验方、秘方和技法并进行开发研究。
  • The draft has not been published in full, so no article numbers, effective date, registration procedure or recognition thresholds are available; planning should rest on the official record as it appears.
    草案尚未公布全文,条款编号、生效日期、登记程序与认定门槛均无从确认;相关规划应以官方后续发布为准。
  • The IP Protection and Application 15th Five-Year Plan (State Council document No. 30 of 2026, issued on 27 July 2026) already lists “issuing the Regulation on the Protection of Traditional Chinese Medicine Knowledge” and strengthening access and benefit-sharing systems for traditional knowledge and folk literature and art.
    《知识产权保护和运用”十五五”规划》(国发〔2026〕30号,国务院2026年7月27日印发)已明确”出台中医药传统知识保护条例”,并加强传统知识、民间文艺等获取和惠益分享制度建设。
  • The same Plan directs improvement of intellectual property protection rules for algorithms and AI-generated output and exploration of data intellectual property protection rules, matters relevant to digital health and AI-assisted research.
    同一规划还提出完善算法、人工智能生成物等知识产权保护规则,探索构建数据知识产权保护规则,与数字健康及人工智能辅助研究密切相关。
  • The revised Trademark Law was adopted on 26 June 2026 and takes effect on 1 January 2027; it writes the principle of good faith into the law and targets bad-faith filings, trademark hoarding and agency conduct.
    新修订《商标法》于2026年6月26日通过、2027年1月1日施行,将诚实信用原则写入法律,并针对恶意抢注、商标囤积及代理行为作出规范。

Traditional Chinese Medicine Knowledge Protection: What the September 2026 Draft Regulation Means for Foreign Pharmaceutical and Healthcare Companies | 中医药传统知识保护:2026年9月国务院常务会议审议通过条例草案对外资医药与大健康企业的意义

Overview

On 18 September 2026, the State Council executive meeting reviewed and approved in principle the Draft Regulation on the Protection of Traditional Chinese Medicine Knowledge. In the official account, traditional Chinese medicine theory, techniques and formulas are described as important resources for China’s own innovation, and the requirement is to comprehensively strengthen their protection and management. The draft has not yet been published in full.

For foreign pharmaceutical, healthcare and wellness companies working in or with China, the development matters for a practical reason. It sits alongside a wider set of intellectual property measures that took effect or moved through the system in 2026, from the revised Trademark Law to the IP Protection and Application 15th Five-Year Plan. Together they shape how traditional knowledge, research collaboration and brand assets are documented and defended.

This article sets out the official wording, the protection system as described, the institutional arrangements in the 15th Five-Year Plan, and the practical points foreign companies may wish to consider. It deliberately does not speculate beyond the official record.

The September 2026 decision

The executive meeting approved the draft and set the direction of policy. Traditional Chinese medicine theory, techniques and formulas are treated as important resources for China’s own innovation, and the task set is to comprehensively strengthen protection and management.

The regulation is to establish a protection system for traditional Chinese medicine knowledge. Under that system, after registration and review-based recognition, a holder enjoys a set of rights: to indicate identity, to transmit and use the knowledge, to give informed consent, to share in benefits, to integrity protection, and to require disclosure of source.

The official account also encourages medical institutions to proactively investigate and discover traditional Chinese medicine proven formulas, secret formulas and techniques, and to carry out development and research on them.

Because the full text has not been published, no article numbers, effective date, registration procedure or definitional thresholds are available. Companies should treat any such details as pending until an official release appears, and should not rely on descriptions that circulate without an official source.

What the 15th Five-Year Plan already provides

The draft regulation is not an isolated initiative. The IP Protection and Application 15th Five-Year Plan (State Council document No. 30 of 2026, issued on 27 July 2026) had already placed it within a wider programme.

The Plan calls for accelerating improvement of the patent-related legal system, for comprehensively revising the Trademark Law and its implementing regulations, and for issuing the Regulation on the Protection of Traditional Chinese Medicine Knowledge. It also directs strengthening access and benefit-sharing systems for traditional knowledge, folk literature and art, and improving intellectual property protection rules for algorithms and AI-generated output as well as for platform-economy development. It further calls for exploring data intellectual property protection rules.

The Plan sets out milestones. By 2030, China’s comprehensive intellectual property strength and international competitiveness are to be further enhanced, with decisive progress in building an intellectual property power. Looking to 2035, comprehensive intellectual property competitiveness is to rank among the world’s leading.

For a company mapping its China research and brand strategy, the Plan is useful because it shows the direction of travel across several instruments at once rather than the detail of a single new rule.

Adjacent intellectual property developments in 2026

A nationwide briefing tour on new intellectual property rules began in Jinan on 20 September 2026, covering the Shandong and Anhui region. The briefings addressed three instruments.

The revised Trademark Law writes the principle of good faith into the law, targets bad-faith filings and the hoarding of trademarks, tightens supervision of trademark agencies and strengthens industry credit constraints. It was adopted on 26 June 2026 and takes effect on 1 January 2027.

The revised Regulation on the Protection of Layout Designs of Integrated Circuits brings layout designs performing functions such as integrated photonics and quantum into the statutory scope of protection and establishes an originality declaration system.

The revised Measures for the Prioritised Examination of Patents steer prioritised examination resources toward emerging industries and key core technology programmes, and establish a central-local coordination mechanism.

Read together with the traditional knowledge regulation, these measures point in a consistent direction: more explicit documentation of what is claimed, who holds it and where it came from.

Practical implications for foreign pharmaceutical and healthcare companies

Due diligence on traditional knowledge. Where a project touches formulas, techniques or sources of traditional knowledge, the rights described in the official account — identity, transmission and use, informed consent, benefit sharing, integrity protection and disclosure of source — suggest that provenance and consent questions may become part of the record. Companies may wish to document how a formula or technique was obtained and on what terms.

Collaboration agreements. Research with hospitals, institutes and practitioners should be documented, with clarity on background and foreground rights, on publication, and on how jointly created results are handled.

Patent and brand layout. The Plan’s direction on patents and the revised Trademark Law both reward early, well-documented filing strategies. A portfolio that depends on distinctive names and marks should be checked against the good-faith and bad-faith filing provisions as they take effect.

Digital and AI-related work. The Plan’s references to algorithms, AI-generated output and data intellectual property are relevant to digital health, AI-assisted screening and data-driven research, where ownership of outputs and datasets is often unsettled.

Watch the official record. Because the draft regulation is not yet published in full, the specific registration route, recognition criteria and benefit-sharing mechanics remain to be seen. Planning should be revisited when the text and any supporting measures are released.

Related considerations

Foreign-invested companies in the healthcare and wellness sectors already work within sector-specific rules on drugs, devices, healthcare services and advertising. The traditional knowledge regulation adds a knowledge-protection layer rather than replacing those rules. Keeping the two layers distinct — what may be made and sold, and what knowledge may be used and on what terms — helps avoid conflating a licensing question with a market-access question.

Sources

  • 国家知识产权局(《知识产权保护和运用”十五五”规划》专栏): https://www.cnipa.gov.cn/col/col3692/index.html
  • 酒泉市公安局(《知识产权保护和运用”十五五”规划》国发〔2026〕30号全文转载): https://gaj.jiuquan.gov.cn/gaj/c106483/202609/856895252998428d9990e67d9af39108.shtml
  • 国家知识产权局(官网,9月工作动态): https://www.cnipa.gov.cn/?filter=0
  • 大众网滨州(知识产权新规全国巡回宣贯,9月20日济南,9-23): https://www.toutiao.com/article/7688564714451780098/
  • 中国政府网: https://www.gov.cn/

中医药传统知识保护:2026年9月国务院常务会议审议通过条例草案对外资医药与大健康企业的意义

概述

2026年9月18日,国务院常务会议审议通过《中医药传统知识保护条例(草案)》。官方表述指出,中医药理论、技术和方药是我国自主创新的重要资源,要全面加强保护管理。该草案尚未公布全文。

对在华开展业务或与中国合作的外资医药、医疗健康与大健康企业而言,这一进展具有现实意义:它与2026年已经施行或正在推进的一揽子知识产权举措并列,从新修订《商标法》到《知识产权保护和运用”十五五”规划》,共同影响传统知识、研究协作与品牌资产的记录与维护方式。

本文梳理官方原文表述、条例拟确立的保护制度、规划中的制度安排,以及外资企业可能关注的实务要点,并刻意不作出超出官方记录范围的推断。

2026年9月的决定

国务院常务会议审议通过草案并确定了政策方向。中医药理论、技术和方药被视为我国自主创新的重要资源,任务要求是全面加强保护管理。

条例将建立中医药传统知识保护制度。在该制度下,经登记并审核认定后,持有人享有一组权利:表明身份、传承使用、知情同意、利益分享、完整保护、要求说明来源。

官方表述还鼓励医疗机构主动调查发现中医药验方、秘方和技法,并进行开发研究。

由于全文尚未公布,条款编号、生效日期、登记程序与认定门槛均无从确认。企业宜将此类细节视为待定,直至官方发布为止,不应依赖没有官方出处的描述。

“十五五”规划已作出的安排

该条例草案并非孤立举措。《知识产权保护和运用”十五五”规划》(国发〔2026〕30号,国务院2026年7月27日印发)已把它纳入更宏大的部署。

规划提出加快完善专利相关法律制度,推动商标法及其实施条例全面修改,并出台中医药传统知识保护条例。规划还提出加强传统知识、民间文艺等获取和惠益分享制度建设,完善算法、人工智能生成物以及与平台经济发展相关的知识产权保护规则,并探索构建数据知识产权保护规则。

规划设定了节点目标:到2030年,知识产权综合实力和国际竞争力进一步增强,知识产权强国建设取得决定性进展;展望2035年,知识产权综合竞争力跻身世界前列。

对正在规划中国研究与品牌战略的企业而言,该规划的价值在于,它一次性展示了多项制度工具的共同走向,而不只是一条新规的细节。

2026年相邻的知识产权进展

2026年9月20日,知识产权新规全国巡回宣贯在济南启动,覆盖山东、安徽片区。宣贯围绕三件法规展开。

新修订《商标法》将诚实信用原则写入法律,遏制恶意抢注、囤积商标,严格商标代理监管,强化行业信用约束。该法于2026年6月26日通过,2027年1月1日施行。

新修订《集成电路布图设计保护条例》将集成光子、量子等功能的集成电路布图设计纳入法定保护范围,并建立独创性声明制度。

修订后的《专利优先审查管理办法》使优先审查资源向新兴产业、关键核心技术攻关倾斜,并建立央地协同机制。

与中医药传统知识保护条例合并来看,这些举措指向一个一致的方向:对主张什么、由谁持有、来自何处作出更明确的记录。

对外资医药与大健康企业的实务影响

传统知识尽职调查。 当项目涉及方药、技法或传统知识来源时,官方表述中的权利——表明身份、传承使用、知情同意、利益分享、完整保护、要求说明来源——提示来源与同意问题可能进入记录范围。企业宜留存取得方药或技法的途径与条件的书面材料。

合作协议。 与医院、科研院所及从业者的研究合作应有书面安排,就背景权利与前景权利、发表,以及共同形成成果的处理作出清晰约定。

专利与品牌布局。 规划在专利方面的方向与新修订《商标法》都倾向于奖励尽早且记录充分的申请策略。依赖独特名称与标识的资产组合,宜在新法施行后比照诚实信用与恶意申请相关条款作一次核对。

数字与人工智能相关工作。 规划中关于算法、人工智能生成物与数据知识产权的表述,与数字健康、人工智能辅助筛查及数据驱动研究相关,而这些领域中成果与数据集的归属往往并不确定。

关注官方记录。 由于条例草案尚未公布全文,具体登记路径、认定标准与惠益分享机制仍有待观察。待文本及配套办法发布后,宜重新审视既有规划。

相关考虑

医药与大健康领域的外商投资企业,本就需遵循药品、器械、医疗服务与广告等分行业规则。中医药传统知识保护条例增加的是一个知识保护层面,而非取代上述规则。把两个层面区分开来——可以制造与销售什么,以及可以何种条件使用何种知识——有助于避免把许可问题与市场准入问题混为一谈。

来源

  • 国家知识产权局(《知识产权保护和运用”十五五”规划》专栏):https://www.cnipa.gov.cn/col/col3692/index.html
  • 酒泉市公安局(《知识产权保护和运用”十五五”规划》国发〔2026〕30号全文转载):https://gaj.jiuquan.gov.cn/gaj/c106483/202609/856895252998428d9990e67d9af39108.shtml
  • 国家知识产权局(官网,9月工作动态):https://www.cnipa.gov.cn/?filter=0
  • 大众网滨州(知识产权新规全国巡回宣贯,9月20日济南,9-23):https://www.toutiao.com/article/7688564714451780098/
  • 中国政府网:https://www.gov.cn/

Foreign-Invested R&D Centres in China: Support Policies, Imported Research Supplies and IP Positioning under the 2026 Action Plan

  • The Action Plan for Stabilising and Optimising Foreign Investment (MOFCOM, NDRC and MOF, document No. 97 of 2026, completed on 16 June 2026 with State Council approval) devotes Part Two, item (7) to vigorously attracting foreign-invested enterprises to establish R&D centres in China.
    《利用外资固稳促优行动方案》(商务部、国家发展改革委、财政部,商资发〔2026〕97号,经国务院同意,2026年6月16日成文)第二部分第(七)条专门规定,大力吸引外资企业在华设立研发中心。
  • The official wording lists five supporting elements: improved support policies, easier introduction of foreign high-level talent, open innovation platforms and practical training bases and new-type R&D institutions, greater support for transforming innovation results, and import tax preferences for scientific research supplies in accordance with law.
    官方原文列出五项支持要素:完善外资研发中心支持政策,便利外籍高层次人才引进,支持设立开放式创新平台和实训基地、发展新型研发机构,加大创新成果转化支持力度,依法享受进口科研用品税收优惠政策。
  • The import-tax element is expressed as “in accordance with law”: the Action Plan affirms the entitlement rather than creating a new concession, and sets out no thresholds, covered-goods list or procedure of its own.
    进口税收环节的表述为”依法享受”:行动方案确认该项待遇,而非另设新的优惠,其本身并未规定门槛、适用物品清单或办理程序。
  • Adjacent provisions widen the downstream routes for results: segmented drug production rules, further pilot regions for biotechnology and wholly foreign-owned hospitals, commercial insurance coverage for more innovative drugs and devices, and platforms easing access to pharmaceutical retail channels.
    相邻条款拓宽了成果的下游路径:药品分段生产实施细则,生物技术与外商独资医院领域试点区域进一步扩大,更多创新药械纳入商业保险保障范围,以及便利进入药品零售渠道的行业协作平台。
  • An R&D centre, a manufacturing company and a regional headquarters carry different licences and supervisory expectations, and the ownership of research results should be settled in employment contracts and inter-company agreements rather than left implicit.
    研发中心、生产性公司与地区总部承载的牌照与监管期待不同;研究成果的归属应在劳动合同与集团间协议中明确,而非留待默认。
  • Technology moving across the border follows classified administration: free-category technology contracts are handled through registration, while restricted-category technology requires licensing.
    跨境技术流动适用分类管理:自由类技术合同通过登记办理,限制类技术需取得许可。

Foreign-Invested R&D Centres in China: Support Policies, Imported Research Supplies and IP Positioning under the 2026 Action Plan | 外资研发中心在华:2026年行动方案下的支持政策、进口科研用品与知识产权布局

Overview

The Action Plan for Stabilising and Optimising Foreign Investment (MOFCOM, NDRC and MOF, document No. 97 of 2026, completed on 16 June 2026 with State Council approval) contains a dedicated measure on R&D centres. Under Part Two, item (7), it calls for vigorously attracting foreign-invested enterprises to establish R&D centres in China, with five supporting elements set out below.

An R&D centre in China is not simply a cost centre attached to a factory. It sits where market access, tax and intellectual property meet, and its value depends on whether research results become assets the group can protect, license and operate. This article sets out the official wording, the tax position of imported research supplies, how a centre differs from a factory or a regional headquarters, and the steps that turn a research presence into a productive one.

The measure in the 2026 Action Plan

The provision is short and programmatic, with five building blocks:

  • Improving support policies for foreign R&D centres. The Plan does not restate the criteria; it directs that the support framework be improved.
  • Facilitating the introduction of foreign high-level talent. Talent mobility is part of the R&D-centre package, linking the measure to the work-permit and talent-administration regime.
  • Supporting open innovation platforms, practical training bases and new-type R&D institutions. This recognises centres that collaborate with universities, institutes and industrial partners rather than operating as closed corporate laboratories.
  • Increasing support for the transformation of innovation results. Commercialisation, not only discovery, is written into the measure.
  • Enjoying import tax preferences for scientific research supplies in accordance with law. The Plan affirms the entitlement by reference to the applicable law rather than creating a concession of its own.

Two adjacent provisions frame the demand side. Part One, item (1), on services-sector opening, calls for steadily expanding pilot openings for vocational-skills training institutions, vocational colleges and high-level science, engineering, agriculture and medical universities, and for supporting Beijing’s national comprehensive demonstration zone for services opening, with pioneering measures in the digital economy and healthcare. Part One, item (3) calls for promptly issuing implementation rules for segmented drug production, seeking approval to further expand pilot regions for biotechnology and wholly foreign-owned hospitals, supporting insurers in bringing more innovative drugs and devices into commercial insurance coverage, and building platforms that ease the entry of foreign-invested enterprises’ drugs into pharmaceutical retail channels.

Imported research supplies: what “in accordance with law” means in practice

The import-tax element is deliberately general. The Plan affirms that foreign R&D centres may “enjoy import tax preferences for scientific research supplies in accordance with law”, and sets out no thresholds, covered-goods list or procedure of its own. Those details live in the import tax policy for scientific and technological innovation and in the provincial qualification review measures that implement it.

The consequence is procedural rather than interpretive. A centre intending to rely on the preference should confirm with the competent commerce, finance, customs and tax authorities the framework in force and the applicable qualification criteria. It should keep documentary evidence of its research substance — investment or research input, full-time research personnel, equipment purchased — because qualification is assessed against such indicators rather than the centre’s name. It should also verify item by item that the goods it wishes to import meet the applicable conditions, since the preference is bounded by those conditions rather than being a general exemption.

R&D centre, factory and regional headquarters: three different positions

A manufacturing company holds production-related licences and is assessed on output, quality and environmental performance; a regional headquarters is mainly a management, co-ordination and shared-service vehicle; an R&D centre is oriented to research and to the transformation of results. The difference matters in three places.

Licensing and approvals. The approvals, filings and supervisory expectations for a research entity differ from those for a production entity. A group planning to move a project from laboratory to pilot to production should design the entity chain in advance rather than assume that the R&D entity can carry the whole pipeline.

Intellectual-property ownership. Results created by employees in the course of their work raise questions of ownership and reward, which should be settled in employment contracts and internal rules and, where group companies are involved, in inter-company agreements on ownership, licensing and transfer.

Technology flows across the border. China administers technology import and export through classified management: free-category technology contracts are handled through registration, restricted-category technology requires licensing. A centre licensing technology to its overseas parent, or introducing technology from abroad, should complete the applicable formalities; the classification of the specific technology determines the route.

Turning results into protectable, operable assets

Patent layout. Filing strategy should be part of project design — deciding early which results are filed, where and in whose name. The revised Measures for the Prioritised Examination of Patents (State Intellectual Property Office Order No. 85), published on 28 July 2026 and effective from 1 September 2026, replaced the 2017 measures and steer fast-track examination toward high-quality applications serving emerging and future industries. For a portfolio concentrated in such fields, prioritised examination is one available accelerator; the substantive requirements and the grounds on which it will not be granted should be checked against the current measures, and the service carries no additional fee.

Contractual architecture. Collaboration with universities, institutes and partners should be documented, with clarity on background and foreground rights, publication and the treatment of jointly created results.

Commercialisation pathway. The emphasis on result transformation, read with the healthcare openings above, suggests that centres should plan the downstream route from the outset: pilot and scale-up capacity, approvals, and the commercial channels available.

Service safeguards

The Plan also addresses what happens after a project lands: it calls for fully implementing national treatment for foreign-invested enterprises and for a special rectification campaign in government procurement to remove barriers; it strengthens the “Invest in China” brand, provides for monthly roundtable meetings with foreign-invested enterprises, and establishes dedicated task forces for key foreign investment projects to provide “point-to-point” service.

Practical steps

  1. Read item (7) with items (1) and (3), which determine where results can go.
  2. Settle the entity design — R&D, pilot and production entities, and any regional headquarters — and map licences accordingly.
  3. Document the centre’s research substance from the start, so that qualification reviews rest on evidence rather than assertion, and confirm the current import-tax policy and its conditions before committing to equipment purchases.
  4. Write intellectual-property arrangements into employment contracts and inter-company agreements, covering ownership, licensing, transfer and cross-border technology flows.

Related reading

  • The Action Plan for Stabilising and Optimising Foreign Investment (document No. 97 of 2026).

Sources

  • 湖南省人民政府(《利用外资固稳促优行动方案》官方英文全文,含第(七)条研发中心原文): https://www.hunan.gov.cn/zqt/zcsd/202607/34034823/files/7660c23769ae4f51ac21a456fe4e0ea5.pdf
  • 江苏省知识产权局(关于修改《专利优先审查管理办法》的说明): https://jsip.jiangsu.gov.cn/art/2026/9/20/art_76183_11832138.html
  • 浙江省市场监督管理局(国家知识产权局关于做好《专利优先审查管理办法》有关实施工作的通知): https://zjamr.zj.gov.cn/col/col1229094027/art/2026/art_c86f0eda26b8439d806be9a748519f47.html
  • 国家知识产权局(官网): https://www.cnipa.gov.cn/
  • 商务部(官网): https://www.mofcom.gov.cn/

外资研发中心在华:2026年行动方案下的支持政策、进口科研用品与知识产权布局

概述

《利用外资固稳促优行动方案》(商务部、国家发展改革委、财政部,商资发〔2026〕97号,经国务院同意,2026年6月16日成文)中就研发中心设有专门条款。方案第二部分第(七)条提出,大力吸引外资企业在华设立研发中心,并列出以下五项支持要素。

对外资集团而言,在华研发中心并非附属于工厂的成本单元。它处在市场准入、税收与知识产权三条政策线的交汇处,其价值取决于研究成果能否转化为集团可保护、可许可、可运营的资产。本文梳理该条官方原文、进口科研用品的税收位置、研发中心与生产实体及地区总部在牌照与知识产权层面的差异,以及把研发存在变成研发产出的实务步骤。

2026年行动方案中的该条内容

该条文字简短、方向明确,由五个要素构成:

  • 完善外资研发中心支持政策。 方案本身未重述具体标准,而是要求把支持政策框架加以完善。
  • 便利外籍高层次人才引进。 人才流动被纳入研发中心政策的整体安排,与工作许可、人才管理等制度相衔接。
  • 支持设立开放式创新平台、实训基地,发展新型研发机构。 这认可了研发中心与高校、科研院所、产业伙伴协作的模式,而非仅作为封闭的企业实验室运行。
  • 加大创新成果转化支持力度。 转化与发现并重,被写入条款之中。
  • 依法享受进口科研用品税收优惠政策。 方案以援引现行法律的方式确认该项待遇,而非另行创设一项新的优惠。

两条相邻条款界定了需求侧。第一部分第(一)条关于深化服务业领域开放,提出稳步扩大职业技能培训机构、职业院校、高水平理工农医类大学对外开放试点;支持北京提升国家服务业扩大开放综合示范区建设水平,推动数字经济、医药健康等现代服务业重点领域开放举措先行先试。第一部分第(三)条关于支持外资参与医药等产业高质量发展,提出抓紧研究出台药品分段生产实施细则;抓紧研究报批进一步扩大生物技术、外商独资医院领域开放试点区域范围;支持保险公司将更多创新药械纳入商业保险保障范围;搭建行业协作平台,便利外资企业生产的药品进入药品零售渠道。

进口科研用品:”依法享受”在实务中的含义

该条中的进口税收要素刻意保持概括。方案确认外资研发中心可”依法享受进口科研用品税收优惠政策”,其本身并未规定门槛、适用物品清单或办理程序。这些细节由支持科技创新的进口税收政策及其配套的省级资格审核办法承载。

因此,实务上的后果是程序性的,而非解释性的。拟适用该待遇的中心,应先与商务、财政、海关与税务主管部门确认现行有效的政策框架与适用资格条件;应保存体现研发实质的证明材料——投资额或研发投入、专职研发人员、累计购置设备——因为资格是按此类指标而非按中心名称判定的;还应逐项核实拟进口物品是否满足适用条件,因为该待遇以这些条件为边界。

研发中心、工厂与地区总部:三种不同位置

生产性公司持有与生产相关的牌照,考核的是产量、质量与环境表现。地区总部主要是管理、协调与共享服务载体。研发中心则面向研究以及成果转化。差异体现在三处。

牌照与审批。 研发主体所适用的审批、备案与监管期待,与生产主体并不相同。计划把项目从实验室推进到中试再到生产的集团,应提前设计主体链条,而不是假定研发主体能够承载整条链路。

知识产权归属。 员工在职完成的成果,其归属与奖酬问题应在劳动合同与内部制度中厘清;涉及集团内公司时,还应在公司间协议中就归属、许可与转让作出约定。若相关安排对此保持沉默,将给集团的全球资产组合带来本可避免的不确定性。

跨境技术流动。 中国对技术进出口实行分类管理:自由类技术合同通过登记办理,限制类技术需取得许可。研发中心向境外母公司许可技术,或从境外引进技术时,应完成相应手续;具体技术的类别决定适用路径。

让成果成为可保护、可运营的资产

专利布局。 申请策略应作为项目设计的组成部分——尽早确定哪些成果申请、在哪里申请、以谁的名义申请。新修订《专利优先审查管理办法》(国家知识产权局令第八十五号)于2026年7月28日公布、自2026年9月1日起施行,取代2017年发布的原办法,优先审查资源向服务新兴产业和未来产业领域的高质量申请倾斜。对于资产组合集中于此类领域的中心,优先审查是可用的一条加速通道;实质性条件以及不予优先审查的情形,应比照现行办法核对,且该服务不收取额外费用。

合同架构。 与高校、科研院所及伙伴开展的协作应有书面安排,就背景权利与前景权利、发表以及共同形成成果的处理作出清晰约定。

转化路径。 方案对成果转化的强调,结合前述医药领域的开放举措,提示中心应从一开始就考虑下游路径——中试与放大能力、所需审批,以及成果产品可用的商业渠道。

服务保障

方案也涉及项目落地之后的事项:全面落实外资企业国民待遇,开展政府采购领域专项整治破除壁垒;强化”投资中国”品牌,每月召开外资企业圆桌会议,并建立重点外资项目工作专班提供”点对点”服务。

实务步骤

  1. 把第(七)条与第(一)条、第(三)条结合阅读,后者决定成果可去向何处。
  2. 先确定主体设计——研发主体、中试与生产主体,以及可能的地区总部——并据此梳理牌照。
  3. 从一开始就记录中心的研发实质,使资格审核以证据而非主张为支撑;并在承诺设备采购之前,与主管部门确认现行进口税收政策及其适用条件。
  4. 把知识产权安排写入劳动合同与公司间协议,覆盖归属、许可、转让与跨境技术流动。

相关阅读

  • 《利用外资固稳促优行动方案》(商资发〔2026〕97号)。
  • 新修订《专利优先审查管理办法》(局令第八十五号)。

来源

  • 湖南省人民政府(《利用外资固稳促优行动方案》官方英文全文,含第(七)条研发中心原文):https://www.hunan.gov.cn/zqt/zcsd/202607/34034823/files/7660c23769ae4f51ac21a456fe4e0ea5.pdf
  • 江苏省知识产权局(关于修改《专利优先审查管理办法》的说明):https://jsip.jiangsu.gov.cn/art/2026/9/20/art_76183_11832138.html
  • 浙江省市场监督管理局(国家知识产权局关于做好《专利优先审查管理办法》有关实施工作的通知):https://zjamr.zj.gov.cn/col/col1229094027/art/2026/art_c86f0eda26b8439d806be9a748519f47.html
  • 国家知识产权局(官网):https://www.cnipa.gov.cn/
  • 商务部(官网):https://www.mofcom.gov.cn/

AI-Related Inventions and Trademark Evidence in China: The September 2026 Examination Standards

  • China’s new Patent Examination Guidelines, in force since 1 January 2026, require that the inventor be a natural person and that an artificial-intelligence system may not be named as an inventor; the guidelines also establish a “holistic determination” approach to assessing patentable subject matter.
    自2026年1月1日施行的新版《专利审查指南》要求发明人必须是自然人,请求书中不得填写人工智能名称,并确立了判断专利保护客体的”整体判断”原则。
  • The Supreme People’s Court’s Opinion on adjudicating artificial-intelligence-related disputes, issued on 7 September 2026, provides in Article 14 that an AI-related invention which “adopts technical means that follow the laws of nature, solves a technical problem and achieves a technical effect consistent with the laws of nature” is protected as a patent-eligible subject matter; the protection is for human creativity, not machine output.
    最高人民法院于2026年9月7日发布的《关于依法审理涉人工智能纠纷案件的意见》第14条明确:涉人工智能发明创造”采用遵循自然规律的技术手段,解决了技术问题,实现了符合自然规律的技术效果的”,依法认定为专利法所保护的客体;专利保护的是人的创造性,而非机器的产出。
  • The administrative rules and the judicial rules now converge for the first time on the question of AI inventions: both insist that patent protection attaches to human inventiveness, while leaving the door open for AI-assisted technical solutions that meet the three-element test of means, problem and effect.
    行政审查规则与司法裁判规则在人工智能发明创造问题上首次形成呼应:二者均强调专利保护指向人的创造性,同时为满足”手段—问题—效果”三要素的人工智能辅助技术方案保留通道。
  • The 15th Five-Year Plan for intellectual-property protection and utilisation calls for improving the protection rules for algorithms, artificial-intelligence-generated outputs and matters related to platform-economy development, signalling a forward-looking policy direction for AI-related IP.
    《知识产权保护和运用”十五五”规划》提出”完善算法、人工智能生成物以及与平台经济发展相关的知识产权保护规则”,为人工智能相关知识产权指明了前瞻性政策方向。
  • The revised Measures for the Prioritised Examination of Patents (Order No. 85) took effect on 1 September 2026, steering fast-track resources toward emerging industries, future industries and key-core-technology breakthroughs; a 26 August 2026 implementation notice clarifies the transition between the old and new regimes.
    新修订《专利优先审查管理办法》(局令第85号)自2026年9月1日起施行,优先审查资源向新兴产业、未来产业和关键核心技术攻关倾斜;2026年8月26日的实施工作通知明确了新旧办法的衔接安排。
  • In trademark practice, the “three-year non-use cancellation” procedure is placing greater weight on electronically admissible evidence that forms a traceable, mutually corroborating chain — contracts, orders, payments, logistics, platform pages and promotional records — narrowing the room for fabricated transaction invoices or formalistic orders to manufacture a veneer of use.
    商标审查中的”连续三年不使用撤销”程序更加重视可采信的电子证据,强调形成可追溯、相互印证的完整链条(合同、订单、付款、物流、平台页面、宣传记录),压缩了以虚假交易发票或形式化订单制造”使用痕迹”的空间。
  • Practical compliance for foreign innovators and brand owners means documenting the human contribution in AI-assisted filings, retaining R&D and data-source trail, preparing a use-evidence archive per mark, and building a defensible evidence chain before any cancellation challenge arises.
    对境外创新主体与品牌权利人而言,实务合规意味着在人工智能辅助申请中记录人的贡献、留存研发与数据来源痕迹、为核心商标建立使用证据档案,并在面临撤销挑战前构建可抗辩的证据链。

AI-Related Inventions and Trademark Evidence in China: The September 2026 Examination Standards | 人工智能相关发明创造的专利确权边界与商标使用证据要求(2026年9月)/ AI-Related Inventions and Trademark Evidence in China

Overview

September 2026 is a notable moment for intellectual-property protection in China: within the same year, the administrative and judicial branches have both drawn the boundary around artificial-intelligence-related creations so as to protect human inventiveness while accommodating AI-assisted technical solutions. The revised Patent Examination Guidelines in force since 1 January 2026 set out who may be named as an inventor and how patentable subject matter is assessed. The Supreme People’s Court’s Opinion on adjudicating AI-related disputes, released on 7 September 2026, gives courts a dedicated rule — Article 14 — on when an AI-related invention is patent-eligible. Around this core, the 15th Five-Year Plan for IP protection (state document No. 30 of 2026) sets a forward-looking direction, the revised Measures for the Prioritised Examination of Patents (Order No. 85) took effect on 1 September 2026, and trademark use-evidence standards are tightening in practice. The combined message for foreign filers: protect and prove human creativity, and keep the documentary trail that demonstrates it.

Administrative examination: the inventor must be human

The revised Patent Examination Guidelines, effective from 1 January 2026, address artificial intelligence directly. First, the inventor must be a natural person; the request form may not list an AI system as an inventor. The legal status of “inventor” is reserved for human beings, and an AI tool is treated as an instrument of the human inventor. Second, the guidelines establish a “holistic determination” (整体判断) principle: the examiner weighs the invention as a whole against the statutory criteria rather than isolating a single feature. This matters for AI-related applications, where the contribution may lie in how a model, algorithm or data pipeline is applied to a concrete technical problem. Applicants should present the solution as an integrated technical whole, not as a bare claim to an abstract idea or to a machine’s output, and should ensure the named inventors are identifiable natural persons.

Judicial stance: the Supreme People’s Court Opinion of September 2026

On 7 September 2026, the Supreme People’s Court issued the Opinion on Adjudicating Cases Involving Disputes over Artificial Intelligence, the first judicial adjudication rule document on AI issued by the country’s highest judicial organ. Its Part Three (Articles 12–16) deals specifically with IP disputes, covering infringement liability, open-source software, patent grant and validity, technology-contract performance and data-use norms.

Article 14 is the provision most directly relevant to patents. It provides that an AI-related invention which “adopts technical means that follow the laws of nature, solves a technical problem and achieves a technical effect consistent with the laws of nature” is, pursuant to law, a subject matter protected by the patent law. The test is the familiar three-element inquiry — technical means, technical problem, technical effect — applied to AI-related subject matter, and the Opinion makes explicit that the patent system protects human creativity, not machine output. This aligns the judicial threshold with the administrative “holistic determination” principle, gives courts a stable published rule, and closes the gap that had existed between how examiners and judges might treat AI-assisted inventions.

Policy layer and prioritised examination

The 15th Five-Year Plan for the Protection and Utilisation of Intellectual Property (State Council document No. 30 of 2026, issued on 27 July 2026) calls for improving protection rules for algorithms, AI-generated outputs and platform-economy matters, and for continuously improving patent-related legal systems. It signals that AI-related IP rules are still being built, on a trajectory of clearer, more purposive protection rather than exclusion.

The revised Measures for the Prioritised Examination of Patents (Order No. 85), effective from 1 September 2026, replace the 2017 version and steer fast-track resources toward high-value applications — those involving emerging industries, future industries or key-core-technology breakthroughs, or industries encouraged by provincial or city-level governments, among other grounds — while imposing sanctions for conduct violating the principle of good faith. A 26 August 2026 implementation notice clarifies the transition: requests submitted from 1 September 2026 follow the new Measures, earlier ones follow the original; re-examination or invalidation prioritised-examination requests are filed online via the “patent事务服务” module of the patent business-processing system; and the new Prioritised Examination Request form applies from 1 September 2026.

Trademark side: use evidence and the three-year non-use cancellation

On the trademark front, the “three-year non-use cancellation” procedure (撤三) is where evidentiary discipline is tightening most visibly. A registered mark not genuinely used for three consecutive years without proper reason may be cancelled on petition, and examination now places greater weight on electronically admissible materials that form a traceable, mutually corroborating chain: a contract, its order, the payment record, the logistics proof, the platform listing and the promotional record should each corroborate the others. An isolated invoice is no longer enough; fabricated transaction invoices, formalistic orders lacking real performance, or defensive “affiliation” arrangements meant merely to manufacture a semblance of use are being squeezed out.

This direction is reinforced by the revised Trademark Law, adopted on 26 June 2026 and taking effect on 1 January 2027 — the first comprehensive amendment since 1983. It writes the principle of good faith into the statute, tightens the registration gate against hoarding and squatting, and strengthens supervision of trademark agencies. For foreign brand owners, stricter use-evidence expectations plus a good-faith statutory regime mean documented, genuine commercial use is the safest way both to keep a mark alive and to defeat a non-use cancellation petition.

Practical steps for applicants

For AI-related patent filings: (1) record the human contribution — ensure named inventors are natural persons and keep internal logs of who directed and performed the inventive work; (2) draft to the three-element test, articulating technical means, problem and effect as an integrated solution; (3) retain the R&D and data-source trail, documenting provenance and licences of any training data; (4) prepare office-action responses early, assembling search reports and prior-art material to show, holistically, why the solution is a lawful technical contribution.

For trademark protection: (1) build a use-evidence archive per core mark, keeping dated contracts, orders, payments, logistics, platform listings and promotional materials; (2) make the chain self-corroborating with independent sources such as platform pages or customs records; (3) tie defensive registrations to real commercial plans, since filings beyond normal business needs carry rejection and bad-faith risk; (4) prepare the cancellation-defence package in advance rather than waiting for a 撤三 petition.

Related reading

  • The revised Patent Examination Guidelines (effective 1 January 2026) on inventor status and subject-matter assessment.
  • The Supreme People’s Court Opinion on adjudicating AI-related disputes (7 September 2026), Part Three on IP disputes.
  • The 15th Five-Year Plan for the Protection and Utilisation of Intellectual Property (State Council document No. 30 of 2026).
  • The revised Measures for the Prioritised Examination of Patents (Order No. 85, effective 1 September 2026).

Sources

  • 国家知识产权局(官网): https://www.cnipa.gov.cn/
  • 林州市人民政府(新版《专利优先审查管理办法》全文转载): https://www.linzhou.gov.cn/2026/09-07/3658810.html
  • 浙江省市场监督管理局(浙江省知识产权局)《关于做好〈专利优先审查管理办法〉有关实施工作的通知》转载: https://zjamr.zj.gov.cn/col/col1229094027/art/2026/art_c86f0eda26b8439d806be9a748519f47.html
  • 最高人民法院(官网): https://www.court.gov.cn/
  • 最高人民法院知识产权法庭《以人为本 智能向善——聚焦〈最高人民法院关于依法审理涉人工智能纠纷案件的意见〉》: https://ipc.court.gov.cn/zh-cn/news/view-6036.html
  • 国家知识产权局《国务院关于印发〈知识产权保护和运用”十五五”规划〉的通知》(国发〔2026〕30号): https://www.cnipa.gov.cn/art/2026/7/31/art_3693_207456.html

人工智能相关发明创造的专利确权边界与商标使用证据要求(2026年9月)/ AI-Related Inventions and Trademark Evidence in China

概述

2026年9月对中国知识产权保护是一个值得关注的节点:行政与司法两个层面在同一年内就人工智能相关创造的边界作出呼应——既保护人的创造性,又为人工智能辅助的技术方案留出空间。自2026年1月1日施行的新版《专利审查指南》明确了谁可被列为发明人,以及如何判断专利保护客体。最高人民法院于2026年9月7日发布的《关于依法审理涉人工智能纠纷案件的意见》首次为法院提供专门规则——第14条,界定涉人工智能发明创造何时构成专利法所保护的客体。围绕这一核心,《知识产权保护和运用”十五五”规划》(国发〔2026〕30号)指明前瞻方向,新修订《专利优先审查管理办法》(局令第85号)自2026年9月1日起施行,商标使用证据标准在实践中持续收紧。对在华提交申请的外国申请人而言,综合信号很明确:保护并证明人的创造性,并保留能够证明这一点的文档痕迹。

行政审查:发明人必须是人

自2026年1月1日施行的新版《专利审查指南》正面回应人工智能问题。第一,发明人必须是自然人,请求书中不得填写人工智能系统作为发明人——”发明人”的法律地位专属于自然人,无论多先进的人工智能工具都只是人类发明人的器具。第二,指南确立”整体判断”原则:审查员将发明作为一个整体与法定要件衡量,而非孤立看待单一特征。这一点对人工智能相关申请尤为关键,其贡献可能体现在模型、算法或数据管线如何被应用于具体技术问题。申请人应将方案作为一体化技术整体呈现,而非对抽象思想或机器产出的简单主张,并确保列名发明人为可识别的自然人。

司法立场:最高人民法院2026年9月意见

2026年9月7日,最高人民法院发布《关于依法审理涉人工智能纠纷案件的意见》,是国家最高审判机关发布的首部涉人工智能司法裁判规则文件。其第三部分(第12至16条)专述知识产权纠纷,涵盖侵权责任认定、开源软件法律责任、专利授权确权、技术合同履行及数据使用规范。

第14条是与专利关系最直接的条款,明确:涉人工智能发明创造”采用遵循自然规律的技术手段,解决了技术问题,实现了符合自然规律的技术效果的”,依法认定为专利法所保护的客体。适用的仍是熟悉的三要素检验——技术手段、技术问题、技术效果——并应用于人工智能相关客体;意见同时明确,专利制度保护的是人的创造性,而非机器的产出。这使司法门槛与行政”整体判断”原则对齐,为法院提供稳定、公开的裁判规则,并弥合了审查员与法官在对待人工智能辅助发明上可能存在的分歧。

政策层与优先审查

《知识产权保护和运用”十五五”规划》(国发〔2026〕30号,2026年7月27日印发)提出”完善算法、人工智能生成物以及与平台经济发展相关的知识产权保护规则”,并承诺持续完善专利相关法律制度。它释放出信号:人工智能相关知识产权的规则仍在构建之中,走向是更清晰、更有针对性的保护,而非简单排斥。

新修订《专利优先审查管理办法》(局令第85号)自2026年9月1日起施行,取代2017年版,将快车道资源导向高价值申请——涉及新兴产业、未来产业或关键核心技术攻关,或省级、设区的市级人民政府重点鼓励产业等情形——并对违反诚信原则的行为设定罚则。2026年8月26日的实施工作通知明确衔接:自9月1日起提交的优先审查请求按新办法办理,此前已提交的按原办法办理;复审或无效宣告案件的优先审查请求通过”专利业务办理系统”的”专利事务服务”模块线上办理;自9月1日起适用新版《专利优先审查请求书》表格。

商标侧:使用证据与”连续三年不使用撤销”

商标领域,”连续三年不使用撤销”(”撤三”)程序的证据纪律收紧得最为明显。注册商标无正当理由连续三年未真实使用的,可经请求被撤销;审查如今更重视可采信的电子材料,强调形成可追溯、相互印证的完整链条:一份合同、对应订单、付款记录、物流凭证、平台在售页面与宣传记录应彼此印证。一张孤立发票已不足够;虚假交易发票、缺乏真实履行的形式化订单,或仅为制造”使用痕迹”而设的防御性挂靠安排,正被持续挤出。

这一方向得到新修订《商标法》的强化。该法于2026年6月26日通过,自2027年1月1日起施行,是1983年施行以来的首次全面修订。修订将诚实信用原则写入法律文本,收紧注册入口以遏制囤积与抢注,并强化对商标代理机构的监管。对境外品牌权利人而言,更严格的使用证据期待叠加诚信法定原则,意味着有据可查的真实商业使用,是维持商标存续、击退”撤三”请求最稳妥的方式。

申请人实务要点

人工智能相关专利申请:一是记录人的贡献——确保列名发明人为自然人,并保留谁主导、谁完成创造性工作的内部记录;二是围绕三要素撰写,将技术手段、问题与效果作为一体化方案阐明;三是留存研发与数据来源痕迹,记录训练数据的来源与授权;四是提前备妥审查意见答复材料,用检索报告与现有技术材料从整体上说明方案为何构成合法技术贡献。

商标保护:一是为核心商标建立使用证据档案,保存带日期的合同、订单、付款、物流、平台在售信息与宣传材料;二是以平台页面、海关记录等独立来源使证据链自我印证;三是将防御性注册与实际商业规划挂钩,明显超出正常经营需要的申请有驳回与恶意认定风险;四是提前备好撤销答辩材料,而非待”撤三”请求来临才着手。

相关阅读

  • 新版《专利审查指南》(2026年1月1日施行)关于发明人地位与客体判断的规定。
  • 最高人民法院《关于依法审理涉人工智能纠纷案件的意见》(2026年9月7日),第三部分专述知识产权纠纷。
  • 《知识产权保护和运用”十五五”规划》(国发〔2026〕30号)。
  • 新修订《专利优先审查管理办法》(局令第85号,2026年9月1日施行)。

来源

  • 国家知识产权局(官网):https://www.cnipa.gov.cn/
  • 林州市人民政府(新版《专利优先审查管理办法》全文转载):https://www.linzhou.gov.cn/2026/09-07/3658810.html
  • 浙江省市场监督管理局(浙江省知识产权局)《关于做好〈专利优先审查管理办法〉有关实施工作的通知》转载:https://zjamr.zj.gov.cn/col/col1229094027/art/2026/art_c86f0eda26b8439d806be9a748519f47.html
  • 最高人民法院(官网):https://www.court.gov.cn/
  • 最高人民法院知识产权法庭《以人为本 智能向善——聚焦〈最高人民法院关于依法审理涉人工智能纠纷案件的意见〉》:https://ipc.court.gov.cn/zh-cn/news/view-6036.html
  • 国家知识产权局《国务院关于印发〈知识产权保护和运用”十五五”规划〉的通知》(国发〔2026〕30号):https://www.cnipa.gov.cn/art/2026/7/31/art_3693_207456.html

China’s patent fast-track gets a 2026 reset: new Prioritised Examination Measures effective 1 September

  • The China National Intellectual Property Administration (CNIPA) published the revised Measures for the Prioritised Examination of Patents (Order No. 85), adopted at its 4th bureau meeting on 16 July 2026 and effective from 1 September 2026, repealing the 2017 version (Order No. 76).
    国家知识产权局公布新修订《专利优先审查管理办法》(局令第85号):2026年7月16日经第4次局务会议审议通过、7月28日公布,自2026年9月1日起施行,2017年版(局令第76号)同时废止。
  • The scope of prioritised examination now covers invention applications in substantive examination that have not yet received a first office action, utility-model and design applications, and re-examination and invalidation cases — while fast-track channels via bilateral/multilateral agreements or IP protection centres are expressly excluded.
    优先审查适用范围涵盖处于实质审查阶段且未作出首次处理的发明专利申请、实用新型和外观设计专利申请,以及复审案件和无效宣告案件;依据双边或多边协议开展优先审查、或经知识产权保护中心预审合格快速审查的,按有关规定处理,不适用本办法。
  • Eligibility for priority centres on innovation value and transformation prospects: emerging and future industries or key-core-technology breakthroughs, industries encouraged by provincial or municipal governments, applicants already industrialising or ready to industrialise (or evidence that others are implementing the invention), first-filing-in-China applications later filed abroad with substantive-examination requests, and other cases of major national or public interest.
    优先审查的适格条件聚焦创新价值与转化前景:涉及新兴产业和未来产业或关键核心技术攻关;涉及省级或设区的市级人民政府重点鼓励的产业;申请人已产业化实施或已做好实施准备、或有证据证明他人正在实施;就相同主题首次在中国申请后又向其他国家或地区提出实质审查请求的;对国家利益或公共利益具有重大意义的其他情形。
  • Reform highlights include tighter management with central-local co-ordination, quality-oriented handling that disciplines violation of good-faith principles, and procedure-level convenience: electronic XML filing, no extra fees for prioritised examination, and clarified processing rules.
    本次修改突出:强化央地协同、规范省级推荐管理;质量导向,对违反诚信原则行为设罚则;程序便利化——采用XML格式电子申请、优先审查不收取额外费用、优化办理手续。
  • For foreign applicants, the key practical point is territorial eligibility: for applications and re-examination requests, the first applicant’s address must be within China (provincial IP offices recommend); overseas and Taiwan-China-region applicants requesting prioritised examination must show the application positively promotes the province’s industrial upgrading and technical iteration, and file in paper form where required.
    对外国申请人最关键的实际要点是地域适格:专利申请与复审案件请求优先审查,第一申请人地址须在中国境内(由省级知识产权局推荐);境外及中国台湾地区申请人提出请求的,其专利申请应对本省产业升级、技术迭代有积极促进作用,且按规定以纸件方式提出。

China’s patent fast-track gets a 2026 reset: new Prioritised Examination Measures effective 1 September | 专利”快车道”2026版重启:新《专利优先审查管理办法》9月1日施行

Overview

On 28 July 2026, the China National Intellectual Property Administration (CNIPA) published the revised Measures for the Prioritised Examination of Patents (《专利优先审查管理办法》) as Order No. 85, adopted at the 4th CNIPA bureau meeting on 16 July 2026. The Measures took effect on 1 September 2026, replacing the 2017 version (Order No. 76). Prioritised examination is China’s formal fast-track within the ordinary examination system — distinct from the PPH-style channels under bilateral/multilateral agreements and from pre-examination-based fast channels at intellectual-property protection centres — and the revision rebalances eligibility, tightens management and modernises procedure. For foreign patent applicants with Chinese filings, the changes affect who can ask for the fast track, how the request is made, and what supporting evidence is expected.

What the revised scope covers

Under the new Measures, prioritised examination applies to:

  • invention applications that are in substantive examination and have not yet received a first office action (首次处理, i.e. the examiner has begun examination and issued a notification);
  • utility-model and design applications;
  • re-examination cases for invention, utility-model and design patents; and
  • invalidation cases for invention, utility-model and design patents.

Expressly outside the Measures are prioritised examination conducted under bilateral or multilateral agreements between CNIPA and foreign offices, and fast-track examination of applications that have passed pre-examination at a national IP-protection centre or rapid-rights-protection centre — those follow their own rules.

The five eligibility grounds

An applicant or re-examination requester may request prioritised examination where the application or case has significant innovation value and transformation prospects and falls under one of five categories:

  1. Emerging and future industries, or key-core-technology breakthroughs (新兴产业和未来产业,或者关键核心技术攻关);
  2. industries encouraged by a provincial or city-level government (省级或设区的市级人民政府重点鼓励的产业);
  3. the applicant has already industrialised or prepared to industrialise, or there is evidence that others are implementing the invention;
  4. the application was first filed in China and a substantive-examination request is later made in another country or region for the same subject matter (a Chinese priority-anchor case); and
  5. other circumstances of major significance to national or public interests.

For invalidation cases, either the invalidation requester or the patentee may request prioritised examination in listed circumstances, including where the patent is involved in infringement disputes and a local IP administration or court is handling the matter.

What changed: three reform themes

1. Adjusted eligibility to serve national priorities. The revision sharpens the focus on high-quality applications in emerging and future industries, adapts the scope to the amended Patent Law and its implementing rules, clarifies circumstances in which prioritised examination will not be granted, and anchors the regime to supporting new-quality productive forces and an innovation-friendly business environment.

2. Full-lifecycle management with a quality orientation. Institutionally, the Measures strengthen central-local co-ordination: CNIPA manages prioritised examination nationwide, receives requests recommended by relevant State Council departments, and reinforces review-resource guarantees; provincial IP offices handle recommendation of requests in their regions and are guided to strengthen management of requesting entities and provide targeted services. In examination organisation, acceptance, review and examination stages are more tightly regulated to raise quality and efficiency. At the source, the Measures emphasise the technical-innovation and transformation value of prioritised cases, strengthen the service guarantee provided by patent agencies to requesting entities, and — notably — impose sanctions for conduct violating the principle of good faith, holding the quality bottom line.

3. Procedure-level convenience. Document requirements are streamlined to make it easier to submit requests; prioritised examination is confirmed to incur no additional fee; and processing rules address issues that practice had flagged, absorbing mature and effective existing approaches.

The filing mechanics

Requests are made electronically in XML format through the patent business-processing system (the relevant module of the system was upgraded online from 1 September 2026). For invention applications, the request must be accompanied by a statement of reasons and supporting documentation including, where applicable, the latest search report of the State Intellectual Property Office or a search report from a foreign office or international organisation, plus evidence of the status of the relevant technical field. Because prioritised examination compresses the examination timeline, the accompanying search report and prior-art material materially determine whether the case can proceed quickly once admitted.

Provincial IP offices make the recommendation for applications and re-examination cases whose first applicant is located in their province; CNIPA receives requests recommended by relevant State Council departments directly. All applicants, re-examination requesters or patentees must consent to the request. For invalidation cases, local IP administrations, courts and arbitration institutions may directly request prioritised examination from CNIPA for patents involved in their cases without provincial recommendation.

What this means for foreign applicants

  • Territorial eligibility is the gate. For patent applications and re-examination cases, prioritised examination requires the first applicant’s address to be in China — the practical route for foreign companies is filing through their Chinese subsidiary, joint venture or licensee as first applicant. Overseas applicants without a Chinese address generally cannot use this fast track for ordinary applications; they instead rely on PPH-type channels or protection-centre pre-examination where applicable.
  • A defined route for overseas and Taiwan-China-region applicants. The Fujian provincial IP authority’s guidance issued with the September 2026 implementation confirms that where overseas and Taiwan-China-region applicants do request prioritised examination, their applications must positively promote the province’s industrial upgrading and technical iteration and effectively lift regional technical capability, and the request must be submitted in paper form. This “contribution to local industry” test is the substantive threshold such applicants should prepare evidence for.
  • First-filing-in-China strategy now links to speed. Category 4 explicitly rewards applicants who first file in China and then seek substantive examination abroad on the same subject matter — a structural incentive relevant to multinationals’ global filing strategies and to their China R&D centres.
  • Good-faith discipline raises documentation standards. The new sanctions for violating good-faith principles mean requests must be supported by genuine evidence (industrialisation, infringement, or other use); speculative or mass requests designed only to jump the queue now carry reputational and procedural risk.
  • Provincial recommendation is a real step. Because provincial IP offices recommend requests, engagement with the province where the Chinese entity is registered matters; provinces with strong innovation-support policies can be expected to prioritise high-value filings aligned with their encouraged industries.

Practical steps

  • Map your China filings to the five eligibility grounds and identify which province will recommend each request.
  • For overseas entities without a Chinese first applicant, confirm the fallback route (PPH, protection-centre pre-examination) and, where provincial prioritised examination is sought, prepare the industrial-upgrade and capability-lift evidence and expect paper filing.
  • Verify that the application has not yet received a first office action before requesting prioritised examination; an application already under active examination is ineligible under the revised definition.
  • Prepare the search-report material: a CNIPA or foreign/international search report strengthens the request.
  • File electronically in XML via the patent business-processing system and watch provincial IP-office implementation guidance issued through late 2026.

Sources

  • 国家知识产权局 — 专利优先审查管理办法(局令第85号,全文): https://www.cnipa.gov.cn/art/2026/7/30/art_74_207457.html
  • 福建省市场监督管理局(福建省知识产权局)— 关于新修订《专利优先审查管理办法》施行有关事项的提示: https://scjgj.fj.gov.cn/zw/tzgg/202609/t20260904_7209087.htm
  • 央视新闻 — 国家知识产权局发布《专利优先审查管理办法》9月1日起施行: https://so.html5.qq.com/page/real/search_news?docid=70000021_2936a6b219783152

Related reading

  • see also: how patents are examined and enforced in China for foreign filers (patent-prosecution-enforcement-china)
  • see also: China’s IP protection centres and fast-track pre-examination routes (ip-protection-centre-fast-track)

专利”快车道”2026版重启:新《专利优先审查管理办法》9月1日施行

概述

2026年7月28日,国家知识产权局公布新修订《专利优先审查管理办法》(局令第85号)。该办法已于2026年7月16日经国家知识产权局第4次局务会议审议通过,自2026年9月1日起施行,2017年版《专利优先审查管理办法》(局令第76号)同时废止。优先审查是中国普通审查体系内的正式快车道——与依据双边或多边协议开展的PPH类通道、以及经知识产权保护中心预审的快速审查通道相区别——本次修订重新校准了适格条件、收紧管理并现代化了程序。对持有中国专利申请的外国申请人而言,变化影响谁能申请快车道、如何提出请求以及需要准备哪些佐证。

修订后的适用范围

依据新办法,优先审查适用于:

  • 发明专利申请:处于实质审查阶段且未作出首次处理的(首次处理指审查员已开始审查并发出通知书);
  • 实用新型和外观设计专利申请;
  • 发明、实用新型和外观设计专利申请的复审案件;
  • 发明、实用新型和外观设计专利的无效宣告案件。

明确不适用本办法的是:依据国家知识产权局与其他国家或地区专利审查机构签订的双边或多边协议开展的优先审查,以及经国家级知识产权保护中心、快速维权中心预审合格后开展的快速审查——这些按其规定处理。

五项适格情形

具有重要创新价值以及转化运用前景的专利申请、复审案件,符合下列情形之一的,专利申请人或复审请求人可以请求优先审查:

  1. 涉及新兴产业和未来产业,或者关键核心技术攻关;
  2. 涉及省级或者设区的市级人民政府重点鼓励的产业;
  3. 专利申请人或复审请求人已经产业化实施或者已经做好产业化实施准备,或者有证据证明他人正在实施其发明创造;
  4. 就相同主题首次在中国提出专利申请后,又向其他国家或地区提出实质审查请求的该中国专利申请(以中国为优先权锚点的案件);
  5. 对国家利益或者公共利益具有重大意义的其他情形。

无效宣告案件方面,涉案专利发生侵权纠纷、当事人已请求地方知识产权局处理或向人民法院起诉等情形的,无效宣告请求人或专利权人均可请求优先审查。

三大改革主题

一、调整适格条件,突出国家需求。 修订进一步聚焦服务新兴产业和未来产业领域的高质量申请;根据新修改的专利法及其实施细则调整适用范围;明确不予优先审查的情形;把制度锚定在支撑新质生产力发展、优化营商环境上。

二、全流程管理、强化质量导向。 制度上强化央地协同:国家知识产权局负责全国管理、受理并审核请求、接收国务院有关主管部门推荐的请求、加强审查资源保障;省级知识产权局负责本区域内请求的推荐,并被引导加强对请求主体的管理和精准服务。审查组织上,受理、审核、审查各环节更加规范,提高审查质量与效率。源头质量上,突出优先审查案件的技术创新和转化运用价值,强化专利代理机构对请求主体的服务保障,并首次对违反诚信原则行为实施相应罚则,筑牢质量底线。

三、优化程序与标准,提升用户体验。 完善现有技术材料提交要求,便利申请人提交请求;明确优先审查服务不收取额外费用;针对实践中反映集中的问题优化具体操作,充分吸纳成熟有效做法。

申请机制

请求须通过专利业务办理系统以XML格式电子提交(2026年9月1日起系统相关模块升级上线)。发明专利申请请求优先审查的,应附理由说明与支持性文件,包括(如适用)国家知识产权局最新检索报告或外国/国际检索报告,以及相关技术领域状况的证明。由于优先审查压缩审查周期,检索报告与现有技术材料在请求获准后能否快速推进起决定性作用。

申请与复审案件的推荐由第一申请人所在地省级知识产权局作出;国家知识产权局直接接收国务院有关主管部门推荐的请求。所有专利申请人、复审请求人或专利权人须一致同意提出请求。无效宣告案件方面,地方知识产权局、人民法院、仲裁机构可直接就涉案专利向国家知识产权局提出优先审查请求,无需省级推荐。

对外国申请人的意义

  • 地域适格是门槛。 专利与复审案件请求优先审查,要求第一申请人地址在中国境内——外国公司的现实路径是以中国子公司、合资企业或被许可方作为第一申请人提交。没有中国地址的境外申请人通常无法为普通申请使用此快车道,只能视情形依托PPH类通道或保护中心预审。
  • 境外及中国台湾地区申请人有明确通道。 福建省知识产权局随2026年9月实施发布的办理提示确认:境外及中国台湾地区申请人请求优先审查的,其专利申请应对本省产业升级、技术迭代具有积极促进作用、能有效带动辖区技术水平提升,且应当以纸件方式提出请求。”对本地产业有贡献”是此类申请人应备好证据的实质性门槛。
  • “先在中国申请”策略与提速挂钩。 第4类情形明确奖励先在中国首次申请、随后就相同主题在境外寻求实质审查的申请人——这是对跨国企业全球申请策略及其在华研发中心的结构性激励。
  • 诚信罚则提高文件标准。 违反诚信原则的新罚则意味着请求须有真实证据支撑(产业化、侵权或其他实施证据);仅为了插队而进行的投机性或批量请求将面临程序与声誉风险。
  • 省级推荐是实打实的一步。 由于请求由省级知识产权局推荐,与中国实体注册地省份的沟通至关重要;创新支持政策强的省份可望优先推荐与其鼓励产业一致的高价值申请。

实务建议

  • 把中国申请对照五项适格情形逐一梳理,确定每项请求将由哪个省份推荐。
  • 无中国第一申请人的境外主体:确认备用通道(PPH、保护中心预审);确需争取省级优先审查的,准备产业升级与能力提升证据并预期纸件提交。
  • 请求前确认申请尚未收到首次审查意见——按修订后的定义,已进入实质审查状态的申请不再适格。
  • 准备检索报告材料:国家知识产权局或外国/国际检索报告可增强请求分量。
  • 通过专利业务办理系统以XML格式电子提交,并跟踪2026年下半年各省知识产权局陆续发布的实施指引。

来源

  • 国家知识产权局 — 专利优先审查管理办法(局令第85号,全文): https://www.cnipa.gov.cn/art/2026/7/30/art_74_207457.html
  • 福建省市场监督管理局(福建省知识产权局)— 关于新修订《专利优先审查管理办法》施行有关事项的提示: https://scjgj.fj.gov.cn/zw/tzgg/202609/t20260904_7209087.htm
  • 央视新闻 — 国家知识产权局发布《专利优先审查管理办法》9月1日起施行: https://so.html5.qq.com/page/real/search_news?docid=70000021_2936a6b219783152

相关阅读

  • 见:外国申请人的中国专利审查与维权(patent-prosecution-enforcement-china)
  • 见:中国知识产权保护中心与预审快车道(ip-protection-centre-fast-track)